Facial rashes

Facial rashes often cause diagnostic confusion but a close examination of the clinical signs should help differentiate the underlying cause (Table 24.6). All facial rashes, by virtue of their visibility, can cause significant distress to the patient.

Table 24.6 Causes of facial rashes

Acne vulgaris

Rosacea

Seborrhoeic eczema

Atopic eczema

Contact eczema

Dermatomyositis

Perioral dermatitis

Photosensitivity

Sarcoidosis

Chronic discoid lupus erythematosus

Systemic lupus erythematosus

Subacute lupus erythematosus

Acne vulgaris

Acne is a very common facial rash occurring in over 85% of adolescents and frequently continuing into early and mid-adult life. Occasionally it can cause profound psychological disturbance and depression, even suicide. The cause is multifactorial but follicular epidermal hyperproliferation, blockage of pilosebaceous units with surrounding inflammation, increased sebum production are critical factors in the pathological process (Fig. 24.20a) as is infection with Propionibacterium acnes.

image

Figure 24.20 Acne vulgaris. (a) Pathophysiology. (b) Skin lesion.

Propionibacterium acnes induced inflammation has recently been shown to occur via activation of Toll-like receptor 2, which leads to production of pro-inflammatory cytokines, e.g. IL-8, IL-12 and TNF-α.

FURTHER READING

Williams HC et al. Acne vulgaris. Lancet 2012; 379:36–372.

Clinical features

Acne presents in areas rich in sebaceous glands such as the face, back and sternal area. The three cardinal features are:

1. Open comedones (blackheads) or closed comedones (whiteheads)

2. Inflammatory papules

3. Pustules (Fig. 24.20b).

The skin may be very greasy (seborrhoea). Rupture of the inflamed lesions may lead to deep-seated dermal inflammation and nodulocystic lesions, which are more likely to cause facial scarring. A premenstrual exacerbation of acne is sometimes noticed. There is a tendency for spontaneous improvement over a number of years but acne can persist unabated into adult life.

A number of clinical variants exist:

image Infantile acne. Facial acne is occasionally seen in infants and is sometimes cystic. It is thought to be due to the influence of maternal androgens and resolves spontaneously.

image Steroid acne. Acne may occur secondary to corticosteroid therapy or Cushing’s syndrome. Clinically the rash often appears as a pustular folliculitis on the trunk without comedones.

image Oil acne. This is an industrial disease seen in workers who have prolonged contact with oils or other hydrocarbons and is common on the legs and other exposed sites.

image Acne fulminans. This is a rare variant seen most commonly in young male adolescents. Severe necrotic and crusted acne lesions appear associated with malaise, pyrexia, arthralgia and bone pain (due to sterile bone cysts). It requires urgent treatment with oral prednisolone (30–40 mg daily) and analgesics followed by a course of oral isotretinoin (see below).

image Acne conglobata’. Cystic acne with abscesses and interconnecting sinuses.

image Acne excoriée’. Deeply excoriated and picked acne with associated scarring. It is much more common in females.

image Follicular occlusion triad’. This is a rare disorder most commonly seen in black Africans. It is characterized by the presence of severe nodulocystic acne, dissecting cellulitis of the scalp (p. 1233) and hidradenitis suppurativa (p. 1198). This may be caused by a problem of follicular occlusion.

FURTHER READING

Goodfield MJ, Cox NH, Bowser A et al. Advice on the safe introduction and continued use of isotretinoin in acne in the UK – 2010. Br J Dermatol 2010; 162:1172–1179.

Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010; 51:248–253.

Treatment

This is aimed at decreasing sebum production, decreasing bacteria, normalizing duct keratinization and decreasing inflammation.

Regular washing with acne soaps to remove excess grease is helpful (normal soaps can be comedogenic). ‘Picking’ should be discouraged.

First-line therapy

Mild acne can respond to a variety of topical agents, e.g. keratolytics (benzoyl peroxide, azelaic acid) or topical retinoids (tretinoin or isotretinoin) or retinoid-like agents (adapalene). Topical antibiotics, e.g. erythromycin or clindamycin, are used for inflammatory acne. All topical agents can cause problems with irritation.

Second-line therapy

image Low-dose oral antibiotic therapy often helps but must be given for at least 3–4 months. Oxytetracycline 500 mg twice daily is often used first. Minocycline 100 mg daily, erythromycin 500 mg twice daily or trimethoprim 100 mg twice daily are also used.

image An extra treatment, cyproterone acetate 2 mg/ethinylestradiol 35 µg (co-cyprindol), is of value in females if there is no contraindication to oral contraception. This acts as a normal combined contraceptive but has antiandrogen activity. It may take 6–8 months to have its maximum effect. There is an increased incidence of DVT.

Third-line therapy

Third-line treatment with an oral retinoid drug (isotretinoin) should be given if:

image the above measures fail

image there is nodulocystic acne with scarring

image there is severe psychological disturbance.

Use of retinoids (isotretinoin or acitretin). Retinoids are synthetic vitamin A analogues that affect cell growth and differentiation. They are very teratogenic. Isotretinoin is a ‘hospital-only drug’ in most countries due to its teratogenicity and is restricted to the use of dermatologists and a few trained family doctors. A pregnancy test, contraceptive advice and signed consent are mandatory prior to its use in fertile women, and pregnancy testing must be repeated monthly during therapy. It is given as a 4-month course at a dose of 0.5–1 mg/kg per day. Over 90% of individuals will respond to this therapy and 65% of people will obtain a long-term ‘cure’.

Patients must avoid pregnancy during therapy and for 1 month after stopping isotretinoin (but for 2 years after stopping acitretin (used only in psoriasis) as it is very lipophilic). Both drugs cause drying of the skin, especially of the lips and nasal mucosa. Hair thinning and exercise-induced myalgia are not uncommon. Blood count, liver biochemistry and fasting lipids need to be monitored during therapy. In a few individuals retinoids may cause depression but it should also be remembered that acne itself has been a cause of suicide.

A number of physical techniques are currently under assessment (e.g. lasers, blue light, microdermabrasion) but they are not as effective as isotretinoin and can be very expensive as repeat treatments are often needed.

Rosacea

Rosacea (Fig. 24.21) is a common inflammatory rash predominantly affecting the face. The onset is usually in middle age and it is commoner in women. It often causes significant psychological distress.

image

Figure 24.21 Rosacea. Papules and pustules on a background erythema. There are no comedones.

The cause is unknown. Theories have suggested an underlying problem in vasomotor stability of blood vessels or a possible role of the skin mite Demodex.

Clinical features

The cardinal features are of facial flushing and inflammatory papules and pustules affecting the nose, forehead and cheeks. The flushing may precede the other signs by some years. There are no comedones. Additional features include dilated blood vessels (telangiectasia), inflammation of the eyelid margins (blepharitis), keratitis and sebaceous gland hypertrophy, especially of the nose. The latter is commoner in men and can cause a disfiguring enlargement of the nose called rhinophyma. The flushing may be exacerbated by alcohol, hot drinks, sunlight and changes in ambient temperature. Prolonged use of topical steroids can exacerbate or trigger the condition. As the disease progresses the flushing may be replaced by a permanent erythema.

Treatment

This is suppressive rather than curative. Long-term use of topical 0.075% metronidazole or topical 15% azelaic acid may help. Avoid topical steroids. A 3-month course of oral tetracycline (500 mg twice daily) is also helpful. Oral metronidazole (400 mg twice daily) or oral isotretinoin (0.5 mg/kg per day) is occasionally given in resistant cases (p. 1213). The papules and pustules tend to respond best to therapy but repeat courses may be necessary. The flushing and erythema are often resistant to treatment but cosmetic camouflage can be helpful for these features. Intense pulse light or pulsed dye laser therapy can help the erythema and telangiectasia but often needs to be repeated as rosacea tends to recur. Rhinophyma can be treated with plastic surgery or by carbon dioxide laser.

FURTHER READING

Van Zuuren EJ, Kramer S, Carter B et al. Interventions for rosacea. Cochrane Database Syst Rev 2011; 3:CD003262.

Perioral dermatitis

Perioral dermatitis is a common rash found around the mouth, especially in young females. The exact cause is unknown but it often has an iatrogenic component as topical steroids often exacerbate the condition in the long term.

Clinical features

It presents with erythema, scaling, papules and occasionally pustules around the mouth. It usually spares a halo of skin immediately adjacent to the lips. Rarely there is involvement around the eyes.

Treatment

Treatment involves stopping topical steroids although they may have to be withdrawn slowly to prevent too severe a rebound after withdrawal. The mainstay of treatment is with a 3–4-month course of low-dose oxytetracycline or erythromycin (both 500 mg twice daily) and topical metronidazole.

FURTHER READING

Lipozencic J, Ljubojevic MD. Perioral dermatitis. Clin Dermatol 2011; 29:157–161.

Blushing

Facial flushing in response to emotional stimuli is a normal physiological response that can be debilitating if it becomes sufficiently frequent to interfere with work and social interaction. Causes may be both psychological and physiological. Non-emotional causes should be excluded, e.g. post-menopause, drugs, and carcinoid syndrome.

Treatment includes cognitive behavioural therapy, cosmetic camouflage, beta-blockers and clonidine. Selective serotonin reuptake inhibitors may help associated depression and anxiety. Botulinum toxin and surgical sympathectomy, advocated by some, are not universally accepted treatments.

Photodermatology

Sunlight. Light in the ultraviolet (UV) part of the spectrum combines short, medium and long wavelengths (UVC, UVB and UVA, respectively). Both UVB and UVA can penetrate the atmosphere and reach the skin. This light energy is potentially mutagenic and carcinogenic but it can also suppress cutaneous inflammation.

Photosensitive rashes usually appear on sites exposed to the sun’s rays, such as the face, the anterior ‘V’ of the chest, the ears and the backs of the hands. Certain ‘protected’ areas are characteristically spared such as under the chin or the upper eyelid and between the finger webs. Porphyria, drug sensitivity and lupus erythematosus should be excluded in all photosensitive patients.

Photosensitive rashes may be divided into photoexacerbated/provoked rashes and the idiopathic photodermatoses (Table 24.7). The former are discussed on pages 535 (SLE), 210 (pellagra) and 1043 (porphyria).

Table 24.7 Differential diagnosis of photosensitive rashes

Photoexacerbated/provoked rashes

Systemic disease

SLE (p. 1219), CDLE (p. 535), SCLE (p. 1218)

Metabolic disease

Porphyrias (pp. 1043), pellagra (p. 210)

Drugs

Thiazides, phenothiazines, tetracyclines, amiodarone

Plant phototoxins

Phytophotodermatitis (photosensitivity induced by contact of the skin with certain plants, e.g. celery, hogweed, rue, lime, fig tree)

Skin disease

Rosacea

 

Rarely atopic eczema, psoriasis, lichen planus (these normally improve in sunlight)

Idiopathic photodermatoses

Polymorphic light eruption

Chronic actinic dermatitis

Solar urticaria

 

CDLE, chronic discoid lupus erythematosus; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus.

Phototherapy and photoprotection

Phototherapy

UVB and UVA both have a suppressive effect on cutaneous inflammation and there is increasing evidence that they can suppress systemic immunoreactivity to some degree. However, both types can cause skin ageing and predispose to skin malignancy if excessive doses are used. This is more of a problem in white-skinned individuals. Unaffected regions of skin or high-risk areas like the scrotum can be screened during phototherapy. UVB is less carcinogenic than UVA.

Narrow-band UVB (311 nm) is used therapeutically in the treatment of eczema and psoriasis (especially in children) and is usually given three times per week for 6–10 weeks. Eye protection needs to be worn during therapy.

Narrow-band UVB is usually used in preference to PUVA. UVA is relatively ineffective on its own so is used in conjunction with a photosensitizer (‘psoralen’), hence the term ‘PUVA’. PUVA is given twice a week and eye protection must been worn for the whole of the treatment day as the psoralen sensitizes the retina. Its use is limited by its carcinogenic potential (especially induction of squamous cell carcinoma of the skin). A maximum dose is given over a lifetime (1000 joules or 200 sessions approximately).

Sunbeds are used for tanning and consist of predominantly UVA light and are therefore rarely effective in treating skin disease. If used frequently there is an increased risk of skin cancer and premature ageing.

Photoprotection

There are two broad classes of sunblock cream: they either absorb UV light (e.g. aminobenzoic acid or methoxycinnamate) or reflect it (e.g. titanium dioxide). Most modern creams protect against UVA and UVB to varying degrees. UVB protection is graded by the ‘sun protection factor’ (SPF): an SPF of 15 implies you can spend 15 times longer in the sun before burning providing it is applied correctly. SPFs above 15 confer little extra protection. There is no standardized way of assessing efficiency against UVA. Some sunscreens (especially aminobenzoates) may rarely cause photosensitization. This can be proven by photopatch testing.

Idiopathic photodermatoses

Polymorphic light eruption (PLE)

This is the most common photosensitive eruption in temperate regions, affecting up to 10–20% of the population. It is most common in young women. In many it is mild and often goes undiagnosed. An itchy rash appears some hours after sun exposure which is strictly confined to the exposed sites. Lesions may be papules, vesicles or plaques. They can last for several hours or several days. The condition starts in spring and often improves during the summer because of skin ‘hardening’.

FURTHER READING

Honigsmann H. Photodermatology. Eur J Dermatol 2009; 6:658–6562.

Lehmann P. Sun exposed skin disease. Clin Dermatol 2011; 29:180–188.

Treatment

Avoidance of sunlight and the use of sunblocks are helpful in mild cases. Topical steroids help treat an attack. In those individuals who only get PLE after very intense sun exposure (e.g. on sunny holidays) a short course of oral prednisolone (30 mg daily for 7–10 days) will often prevent or treat an attack. For resistant cases ‘desensitization’ with low-dose PUVA (or narrow-band UVB) in the springtime may be required but patients will need to ‘top up’ their sun exposure from natural sunlight during the summer to keep their skin desensitized.

Chronic actinic dermatitis (photosensitive eczema, actinic reticuloid)

This is a relatively rare type of eczema occurring in a photosensitive distribution over the face, neck and hands. It typically affects middle-aged or elderly males. There may be a pre-existing eczema so the subsequent development of photosensitivity is often missed. This is further confounded by the fact that the eczema usually will spread to affect skin not exposed to sunlight, and the patient can become erythrodermic. The skin has typical features of eczema but there is often marked skin thickening. Histology is often atypical and can look almost lymphoma-like. The diagnosis can be confirmed by specialist monochromator light-testing. The most severe cases can be exacerbated by even artificial lighting as these patients can become exquisitely photosensitive.

Treatment

This consists of strict avoidance of sunlight including high-factor sunblocks and screening of house and car windows. Topical steroids and emollients are useful in milder cases. Oral prednisolone may be needed and azathioprine (1–2 mg/kg daily) is used for long-term suppression. Low-dose phototherapy under steroid cover may help with ‘desensitization’.

Solar urticaria

This is extremely rare. Itchy urticarial lesions occur within minutes of sun exposure and characteristically settle within 1–2 hours. Sun avoidance, sunblocks, H1 antihistamines and low-dose phototherapy are all used in treatment.

Erythroderma

Erythroderma, meaning ‘red skin’, refers to the clinical state of inflammation or redness of all (or nearly all) of the skin. It is sometimes called exfoliative dermatitis, but dermatitis is not always present.

Aetiology

There are a number of underlying causes (Table 24.8); previous skin disease and drugs are the most common.

Table 24.8 Causes of erythroderma

Common

Atopic eczema

Psoriasis

Drugs (e.g. sulphonamides, gold, sulfonylureas, penicillin, allopurinol, captopril)

Seborrhoeic eczema

Idiopathic

Rare

Chronic actinic dermatitis

Cutaneous T cell lymphoma (Sézary’s syndrome)

Malignancy (especially leukaemias)

Pemphigus foliaceus

Pityriasis rubra pilaris (a hereditary disorder of keratinization)

HIV infection

Toxic shock syndrome

Clinical features

It is commoner in males and later in life. Patients often complain of their skin feeling ‘tight’ as well as itchy. Longstanding erythroderma is often associated with hair loss, ectropion of the eyelids and even nail shedding. Systemic symptoms are common such as malaise, pyrexia, widespread lymphadenopathy and other complications (see below). Erythroderma can occasionally lead to death so it should be regarded as a medical ‘emergency’.

Examination should specifically look for pustules and nail changes suggestive of psoriasis.

A skin biopsy may further help to elucidate the cause, especially of cutaneous lymphoma. T cell receptor gene rearrangement studies (looking for evidence of clonal T cell expansion in the skin and blood) are also useful in the diagnosis of lymphoma. Lymph node biopsy is also useful in lymphoma. In non-malignant disease lymph nodes normally show nonspecific, reactive (dermatopathic) changes. A number of cases defy an exact diagnosis.

Complications

The skin is one of the largest organs of the body, so perhaps it is no surprise that inflammation of the whole organ can cause metabolic and haemodynamic problems. Examples are:

image High-output cardiac failure from increased blood flow

image Hypothermia from heat loss

image Fluid loss by transpiration

image Hypoalbuminaemia

image Increased basal metabolic rate

image ‘Capillary leak syndrome’.

Capillary leak syndrome is the most severe complication and has been responsible for a fatal outcome in some cases of psoriasis, although this is extremely rare. It is thought that the inflamed skin releases large quantities of cytokines that cause a generalized vascular leakage. This can cause cutaneous oedema and acute lung injury (p. 883).

Treatment

Treatment of erythroderma is best initiated in hospital. Patients must be kept very warm (with space blankets and heaters). Their vital signs should be monitored regularly, particularly fluid balance. Changes in serum electrolytes and albumin, as well as circulatory status, should be corrected. Swabs should be taken to detect any secondary skin infection.

The skin condition is treated with bed rest and either a bland emollient or a mild topical steroid. All non-essential drugs should be stopped. Where known, the underlying cause should be treated. The blanket use of systemic steroid therapy for erythroderma remains controversial in view of possible side-effects.

Capillary leak syndrome will often require specialized haemodynamic management in an intensive care unit.

Cutaneous signs of systemic disease

Some dermatoses are associated with a variety of underlying systemic diseases. Furthermore, some medical conditions may present with cutaneous features.

Erythema nodosum

Erythema nodosum has a number of underlying causes (Table 24.9). It presents as painful or tender dusky blue-red nodules, commonly over the shins or lower limbs, which fade over 2–3 weeks leaving a bruised appearance (see Fig. 24.39). It is most common in young adults, especially females. It may be associated with arthralgia, malaise and fever. Inflammation occurs in the dermis and the subcutaneous layer (panniculitis).

Table 24.9 Causes of erythema nodosum

Streptococcal infectiona

Drugs (e.g. sulphonamides, oral contraceptive)

Sarcoidosisa

Idiopathica

Bacterial gastroenteritides, e.g. Salmonella, Shigella, Yersinia

Fungal infection (histoplasmosis, blastomycosis)

Tuberculosis

Leprosy

Inflammatory bowel disease

Chlamydia infection

a Common causes.

Treatment is of the symptoms with non-steroidal anti-inflammatory drugs (avoid in pregnancy), light compression bandaging and bed rest, as the condition resolves spontaneously. The underlying cause should be treated. In very persistent cases dapsone (100 mg daily), colchicine (500 µg twice daily) or prednisolone (up to 30 mg daily) can be useful.

Erythema multiforme

Erythema multiforme (EM) is a hypersensitivity rash of acute onset frequently caused by infection or drugs. A cell-mediated cutaneous lymphocytotoxic response is present.

In 50% of cases, the cause is not found but the following should be considered:

image Herpes simplex virus (the most common identifiable cause)

image Other viral infections (e.g. Epstein–Barr virus (EBV), orf)

image Drugs (e.g. sulphonamide, anticonvulsants)

image Mycoplasma infection

image Autoimmune rheumatic disease (e.g. SLE, polyarteritis nodosa)

image HIV infection

image Wegener’s granulomatosis

image Carcinoma, lymphoma.

Clinically the lesions can be erythematous, polycyclic, annular or show concentric rings (‘target lesions’) (Fig. 24.22). Frank blistering is not uncommon. The rash tends to be symmetrical and commonly affects the limbs, especially the hands and feet where palms and soles may be involved. Occasionally, there is severe mucosal involvement leading to necrotic ulcers of the mouth and genitalia, and a conjunctivitis (‘EM major’ – not to be confused with Stevens–Johnson syndrome – see Table 24.10).

image

Figure 24.22 Erythema multiforme major. (a) Target lesions of the palm. (b) Mucosal involvement around the mouth.

Table 24.10 Clinical spectra of erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis

image

The term ‘EM minor’ is used for cases without mucosal involvement.

Erythema multiforme usually resolves in 2–4 weeks. Rarely, recurrent erythema multiforme can occur and this is triggered by herpes simplex infection in 80% of cases.

Treatment

This is symptomatic and involves treating the underlying cause. Some advocate the use of oral steroids in severe mucosal disease but this remains controversial.

Recurrent erythema multiforme can be treated with prophylactic oral aciclovir (200 mg twice daily) even if no cause has been found, as 80% of cases appear to be driven by herpes simplex virus. In resistant cases, azathioprine (1–2 mg/kg daily) is used.

Pyoderma gangrenosum

Pyoderma gangrenosum is a condition of unknown aetiology that presents with erythematous nodules or pustules which frequently ulcerate (Fig. 24.23). The ulcers can be large and grow at an alarming speed. The ulcer has a typical bluish black (‘gangrenous’) undermined edge and a purulent surface (‘pyoderma’). There may be an associated pyrexia and malaise. Biopsy through the ulcer edge shows an intense neutrophilic infiltrate and occasionally a vasculitis but the diagnosis depends mostly on the clinical appearance. The main causes are:

image Inflammatory bowel disease

image Rheumatoid arthritis

image Myeloma, monoclonal gammopathy, leukaemia, lymphoma

image Liver disease (e.g. primary biliary cirrhosis)

image Idiopathic (>20% in some series).

image

Figure 24.23 Pyoderma gangrenosum.

Treatment

This is with very potent topical steroids or 0.1% tacrolimus ointment. High-dose oral steroids may be needed to prevent rapidly progressive ulceration. Oral dapsone and minocycline are also used. Other immunosuppressants, such as ciclosporin, are useful in resistant cases. The underlying cause should be treated.

Acanthosis nigricans

Acanthosis nigricans presents as thickened, hyperpigmented skin predominantly of the flexures (Fig. 24.24). It can appear warty or velvety when advanced. In early life it is seen in obese individuals who have very high levels of insulin owing to insulin resistance (and this is sometimes termed ‘pseudo-acanthosis nigricans’). In older people it normally reflects an underlying malignancy (especially gastrointestinal tumours). Rarely it is associated with hyperandrogenism in females.

image

Figure 24.24 Acanthosis nigricans.

image

Acanthosis nigricans in an obese individual.

Treatment

Topical or oral retinoids (0.5 mg/kg per day) may help (p. 1213), and weight loss is advised in the obese. Any underlying malignancy should be treated.

Dermatomyositis (see also p. 540)

The rash is distinctive and often photosensitive. Facial erythema and a magenta-coloured rash around the eyes with associated oedema are usually present. Bluish red nodules or plaques may be present over the knuckles (Gottron’s papules) and extensor surfaces. The nail folds are frequently ragged with dilated capillaries. The diagnosis is made from the clinical appearance, muscle biopsy, electromyography (EMG) and a serum creatine phosphokinase. Skin biopsy is not diagnostic.

There is a childhood form, which usually occurs before the age of 10 and which eventually resolves. This type is associated with calcinosis in the skin, weak muscles and contractures. Life-threatening bowel infarction can also occur in the childhood form. The adult form usually occurs after the age of 40. Some cases are associated with an underlying malignancy whereas some are associated with other autoimmune rheumatic diseases. This latter group may overlap with scleroderma and lupus erythematosus.

Treatment

Skin disease may respond to sunscreens and hydroxychloroquine (200 mg twice daily) as well as immunosuppressants, e.g. prednisolone, azathioprine or ciclosporin.

Scleroderma

The term scleroderma (see also p. 538) refers to a thickening or hardening of the skin owing to abnormal dermal collagen. It is not a diagnostic entity in itself. Systemic sclerosis and morphea both show sclerodermatous changes but are separate conditions.

Systemic sclerosis (often called scleroderma) has cutaneous and systemic features and is discussed fully on page 538.

Morphea is confined to the skin and usually presents in children or young adults. It is commoner in females and the cause is unknown. Lesions are usually on the trunk and appear as bluish red plaques which progress to induration and then central white atrophy. A linear variant exists in childhood which is more severe as it can cause atrophy of underlying deep tissues and thus cause unequal limb growth or scarring alopecia.

image

Morphea – hyperpigmentation and scarring on the trunk.

Rarely sclerodermatous skin changes may be seen in Lyme disease (acrodermatitis chronica atrophicans), chronic graft-versus-host disease, polyvinyl chloride disease, eosinophilic myalgia syndrome (due to tryptophan therapy) and bleomycin therapy.

Lupus erythematosus (LE)

There are three clinical variants to this disease but some patients may show features of more than one type.

image Chronic discoid lupus erythematosus (CDLE)

image Subacute cutaneous lupus erythematosus (SCLE)

image Systemic lupus erythematosus (SLE).

The aetiology is unknown but variable autoantibodies may be found in all types, suggesting that it is an automimmune disorder. Very rarely it can be induced by certain drugs such as phenothiazines, hydralazine, methyldopa, isoniazid, tetracycline, mesalazine and penicillin.

Chronic discoid lupus erythematosus (CDLE)

CDLE is the most common type of LE seen by dermatologists and more frequently affects females. Clinically it presents with fixed erythematous, scaly, atrophic plaques with telangiectasia, especially on the face or other sun-exposed sites (Fig. 24.25). Hypopigmentation is common and follicular plugging may be apparent. Scalp involvement may lead to a scarring alopecia. Oral involvement (erythematous patches or ulceration) occurs in 25% of cases.

image

Figure 24.25 Chronic discoid lupus erythematosus, showing scaling, atrophy and hypopigmentation.

CDLE may be triggered and exacerbated by UV exposure. A few patients may also suffer with Raynaud’s phenomenon or unusual chilblain-like lesions (chilblain lupus). Only 5% of cases will go on to develop SLE but this is more common in children. Serum anti-nuclear factor (ANF) is positive in 30% of cases.

Skin biopsy shows a dense patchy, dermal cellular infiltrate (mostly T cells) which often is centred on appendages. Epidermal basal layer damage, follicular plugging and hyperkeratosis may be present. Direct immunofluorescence studies of lesional skin may show the presence of IgM and C3 in a granular band at the dermoepidermal junction (‘lupus band’).

Treatment

First-line therapy is with sunscreens and potent topical steroids. Certain oral antimalarials (hydroxychloroquine 100–200 mg twice daily and mepacrine 100 mg daily) can prove very useful and are generally safe for long-term intermittent use. Oral prednisolone is beneficial but its use is limited by its side-effect profile. Azathioprine, retinoids, ciclosporin and thalidomide can be useful in resistant cases.

Prognosis

The disease is usually chronic although it often fluctuates in severity. CDLE remains confined to the skin in most patients and it will eventually go into remission in up to 50% of cases (after many years).

Subacute lupus erythematosus (SCLE)

SCLE is a rare cutaneous variant of LE. It presents with widespread indurated, sometimes urticated erythematous lesions, often on the upper trunk. The lesions can also be annular. Photosensitivity is often a prominent feature. Complications, such as arthralgia and mouth ulceration, are seen but significant organ involvement is rare. ANF and extractable nuclear antibodies (anti-Ro and anti-La) are usually positive (see p. 537).

Treatment is with oral dapsone, antimalarials or systemic immunosuppression (prednisolone and ciclosporin).

Systemic lupus erythematosus (SLE)

(see also p. 535)

The cutaneous involvement of SLE is one of the minor problems of the disease but it may be the presenting feature.

Features include macular erythema over the cheeks, nose and forehead (‘butterfly rash’ – Fig. 24.26). Palmar erythema, dilated nail-fold capillaries, splinter haemorrhages and digital infarcts of the finger tips may also be seen but are not always noticed by the patient. Joint swellings, livedo reticularis and purpura are occasionally seen. Rarely SLE can be complicated by an atypical erythema multiforme-like rash (‘Rowell’s syndrome’).

image

Figure 24.26 Systemic lupus erythematosus – macular erythema on the cheeks (‘butterfly rash’).

Treatment (p. 537) is usually managed by a rheumatologist.

FURTHER READING

Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010; 19:1050–1070.

Pruritus

The pathophysiology of pruritus (itch) is poorly understood but may be due to peripheral mechanisms (as in skin disease), central or neuropathic mechanisms (as in multiple sclerosis), neurogenic (as in cholestasis/µ-opioid receptor stimulation) or psychogenic mechanisms (e.g. parasitophobia). Evidence suggests that low stimulation of unmyelinated C-fibres in the skin is associated with the sensation of itch (high stimulation produces pain). Histamine, tachykinins (e.g. substance P) and cytokines (e.g. interleukin-2) may also play a role peripherally in the skin. The major nerve pathways for itch and the influence of the central nervous system are not well characterized but opioid µ-receptor-dependent processes can regulate the perception and intensity of itch.

Pruritus (see p. 1207, lichen simplex, nodular prurigo/neurodermatitis) in the absence of a demonstrable rash can be caused by a number of different medical problems (Table 24.11).

Table 24.11 Medical conditions associated with pruritus

Iron deficiency anaemia

Internal malignancy (especially lymphoma)

Diabetes mellitus

Chronic kidney disease

Chronic liver disease (especially primary biliary cirrhosis)

Thyroid disease

HIV infection

Polycythaemia vera

Asteatotic eczema and cholinergic urticaria are common causes of pruritus where the rash is often missed. The term idiopathic pruritus or ‘senile’ pruritus probably overlaps with asteatotic eczema and this is common in the elderly.

Treatment involves avoiding soaps and symptomatic measures (as for asteatotic eczema). Phototherapy, low-dose amitriptyline or gabapentin may help intractable cases. Underlying medical problems should be treated.

Sarcoidosis

Sarcoidosis (see also p. 845) is a multisystem granulomatous disorder of unknown aetiology. It may present as reddish brown dermal papules and nodules, especially around the eyelid margins and the rim of the nostrils. More polymorphic lesions (papules, nodules and plaques) may appear on the body. It is most common in black Africans where it is often accompanied by hypo- or hyperpigmentation. Rarely it presents with a bluish red infiltrate or swelling, especially of the nose or ears, called lupus pernio. Both these types of lesion are to be seen anywhere on the body but are common on the face. Erythema nodosum (p. 1216) of the shins is sometimes seen in acute-onset sarcoidosis. Erythema nodosum is an immunological reaction and not due to sarcoid tissue infiltration. Swollen fingers from a dactylitis may also be present. Whilst sarcoidosis may be confined to the skin, all patients should be investigated for evidence of systemic disease (p. 847).

Treatment of cutaneous lesions includes very potent topical steroids (0.05% clobetasol propionate), intralesional steroids, oral steroids and occasionally methotrexate or antimalarials.

FURTHER READING

Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007; 56:69–83.

Neurofibromatosis type 1 (von Recklinghausen’s disease)

Type 1 neurofibromatosis is an autosomal dominant condition with high levels of penetrance. It often presents in childhood with a variety of cutaneous features. Many cases are new mutations in the NF1 gene. Early signs include café-au-lait spots (brown macules, >2.5 cm in diameter and more than five lesions) and axillary freckling. Lisch nodules (hyperpigmented iris hamartomas) may be seen in the eyes by slit lamp examination. Learning difficulties and skeletal dysplasia occur. Later on, fleshy skin tags and deeper soft tumours (neurofibromas) appear and they can progress to completely cover the skin causing significant cosmetic disability. A number of endocrine disorders are rarely associated including phaeochromocytoma, acromegaly and Addison’s disease.

Tuberous sclerosis (epiloia)

The tuberous sclerosis complex (TSC) is an autosomal dominant condition of variable severity which may not present until later childhood. It is characterized by a variety of hamartomatous growths. The three cardinal features are (1) mental retardation, (2) epilepsy and (3) cutaneous abnormalities – but not all have to be present. In most cases, it is due to a mutation in either the TSC1 gene (encodes hamartin) or the TSC2 gene (encodes tuberin). Genetic testing is available but the diagnosis still remains clinical, requiring two major features or one major and two minor features. The skin signs include:

image Adenoma sebaceum (reddish papules/fibromas around the nose)

image Periungual fibroma (nodules arising from the nail bed)

image Shagreen patches (firm, flesh-coloured plaques on the trunk)

image Ash-leaf hypopigmentation (pale macules best seen with UV light)

image Forehead plaque (indurated flesh-coloured patch)

image Café-au-lait patches

image Pitting of dental enamel.

Internal hamartomas can arise in the heart, lung, kidney, retina and CNS. Parents of a suspected case should be carefully examined (under UV light) as they may have a ‘forme fruste’ of the condition, which can manifest just as hypopigmented patches. This and gonadal mosaicism can have genetic implications for future offspring. A large contiguous gene defect may involve TSC2 and PKD1 genes causing tuberous sclerosis and polycystic kidney disease together in the same patient.

FURTHER READING

Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657–668.

Diabetes mellitus

Diabetes mellitus (see also p. 1001) can have a number of cutaneous features. Complications of diabetes itself include:

image Fungal infection (e.g. Candidiasis)

image Bacterial infections (e.g. recurrent boils)

image Xanthomas

image Arterial disease (ulcers, gangrene)

image Neuropathic ulcers.

Specific dermatoses of diabetes include:

image Necrobiosis lipoidica (a patch of spreading erythema over the shin which becomes yellowish and atrophic in the centre and may ulcerate)

image

Necrobiosis lipoidica on the shin in type 1 diabetes mellitus.

image Diffuse granuloma annulare (p. 1212)

image Diabetic dermopathy (red-brown flat-topped papules)

image Blisters (usually on the feet or hands)

image Diabetic stiff skin (tight waxy skin over the fingers with limitation of joint movement owing to thickened collagen – also called cheiroarthropathy).

Chronic liver disease

Chronic liver disease may present with jaundice, palmar erythema, spider naevi, white nails, hyperpigmentation and pruritus.

Porphyria cutanea tarda (PCT, p. 1045) is a rare genetic disorder associated with liver disease usually due to hepatic damage from excessive alcohol consumption or hepatitis C infection. Some 75% of cases are sporadic, 25% familial. Overall, 20% of cases have underlying hereditary haemochromatosis (p. 303). PCT presents clinically on exposed skin with sun-induced blisters, skin fragility, scarring, milia and hypertrichosis. Treatment of the cutaneous features is with repeated venesection and/or very low-dose chloroquine plus avoidance of alcohol. There is anecdotal evidence that specific treatment of hepatitis C will also help the skin, presumably by improving liver function. All people with PCT are at risk of hepatic carcinoma.

FURTHER READING

Elder GH. Alcohol and porphyria cutanea tarda. Clin Dermatol 1999; 17:431–436.

Chronic kidney disease (CKD)

Chronic kidney disease (see also p. 320) is commonly associated with intractable pruritus. Pallor, hyperpigmentation and ecchymoses are commonly seen. Rarely it is associated with non-inflammatory blisters, pseudo-porphyria cutanea tarda and cutaneous calcification. Longstanding renal transplant patients often suffer with recurrent viral warts and squamous cell carcinomas due to the immunosuppression.

‘Nephrogenic fibrosing dermopathy’ (also known as ‘nephrogenic systemic fibrosis’) is a newly described severe scleroderma-like skin disease in a subset of patients who have CKD (usually on dialysis). The disease is rapid in onset (days to weeks) with skin discoloration and thickening, joint contractures, muscle weakness and generalized pain. Widespread tissue fibrosis may ensue, causing severe morbidity. Patients may rapidly become wheelchair-bound. The condition is strongly associated with the contrast medium gadolinium used in MRI scans, and such contrast agents are best avoided in people with low GFRs. There is no accepted treatment but some advocate PUVA and extracorporeal photophoresis. No spontaneous remissions have been recorded. Rapid correction of renal function generally stops the condition progressing.

Calciphylaxis is discussed in Chapter 12.

Thyroid disease (see also p. 937)

Hypothyroidism may cause dry firm gelatinous (myxoedematous) skin with diffuse hair thinning and loss of the outer third of the eyebrows. Hyperthyroidism may be associated with warm sweaty skin and a diffuse alopecia. Graves’ disease is rarely associated with thyroid acropachy (‘clubbing’ with underlying bone changes) and pretibial myxoedema (a red-brown mucinous infiltration of the shins which can become lumpy and tender).

Cushing’s syndrome (see also p. 957)

This may cause hirsutism, a moon face, a buffalo hump, stretchmarks (striae) and a pustular folliculitis (often called steroid acne) of the skin.

Hyperlipidaemias

Hyperlipidaemias (see also p. 1034) can present with xanthomas, which are abnormal collections of lipid in the skin. All people with xanthomas should be investigated for hyperlipidaemia although the most common type, called xanthelasmas (yellow plaques around the eyes), are usually associated with normal lipids. There are a number of other clinical variants of xanthomas such as (1) tuberous xanthoma (firm orange-yellow nodules and plaques on extensor surfaces); (2) tendon xanthoma (firm subcutaneous swellings attached to tendons); (3) plane xanthoma (orange-yellow macules often affecting palmar creases); (4) eruptive xanthoma (numerous small yellowish papules commonly on the buttocks).

Amyloidosis

Macular amyloid is a common purely cutaneous variant seen in Asians. It is characterized by itchy brown rippled macules on the upper back.

Systemic amyloid may be associated with reddish brown papules, nodules or plaques especially around the eyes, the flexural areas and mucosal surfaces. Distinctive periorbital bruising and macroglossia may also be present.

Systemic malignant disease

Certain rashes may be a non-metastatic manifestation of an underlying malignancy: paraneoplastic dermatoses (Table 24.12). Rarely tumours can metastasize to the skin where they normally present as papules or nodules which may proceed to ulcerate.

Table 24.12 Non-metastatic cutaneous manifestations of underlying malignancy

Dermatosis Tumour

Dermatomyositis

Lung, GI tract, GU tract

Acanthosis nigricans

GI tract, lung, liver

Paget’s disease (localized patch of eczema around the nipple)

Ductal breast carcinoma

Erythroderma

Lymphoma/leukaemia

Tylosis (thickened palms/soles)

Oesophageal carcinoma

Tripe palms (velvet palms)

Pulmonary, gastric

Ichthyosis (dry flaking of skin)

Lymphoma

Erythema gyratum repens (concentric rings of erythema, which change rapidly)

Lung, breast

Necrolytic migratory erythema (burning, geographic and spreading annular areas of erythema)

Glucagonoma

FURTHER READING

Abreu Velez AM, Howard MS. Diagnosis and treatment of cutaneous paraneoplastic disorders. Dermatol Ther 2010; 23:662–675.

Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539–551.

Topham E. Cutaneous manifestations of cancer and chemotherapy. Clin Med 2009; 9:375–379.

Bullous disease

Primary blistering diseases of the skin are rare. A variety of skin proteins hold the skin together. Inherited abnormalities or immune damage of these proteins cause abnormal cell separation, inflammation, fluid accumulation and blistering (Fig. 24.27). The level of blistering determines the clinical picture as well as the prognosis. Therefore skin biopsy for light and electron microscopy together with immunofluorescence (IMF) studies is paramount in diagnosis. However, remember that the commonest causes of skin blistering are chickenpox, herpes, impetigo, pompholyx eczema and insect bite reactions, although the latter are often localized.

image

Figure 24.27 Section of the basement membrane zone, showing the structural sites of damage in bullous disorders. LAD, linear IgA disease; EB, epidermolysis bullosa; K, keratin.

Immunobullous disease

Pemphigus vulgaris

Pemphigus vulgaris is a potentially fatal blistering disease occurring in all races but commoner in Ashkenazi Jews and possibly in people from the Indian subcontinent. Onset is usually in middle age and both sexes are affected equally. The development of autoantibodies, e.g. IgG4 against the desmosomal protein desmoglein 1 and 3 is pathogenic in this disease and the autoantibodies can be measured as markers of disease activity. Desmoglein 1 and 3, an adhesion molecule, is expressed in skin and mucosal surfaces, so both will blister. Rarely the disease can be drug induced (e.g. penicillamine or captopril).

Skin biopsy shows a superficial intraepidermal split just above the basal layer with acantholysis (separation of individual cells). In the rarer variant, pemphigus foliaceus (characterized by anti-desmoglein 1 IgG4 autoantibodies), the split is higher in the upper epidermis. As desmoglein 1 is not expressed in oral mucosa, only cutaneous blisters are seen in this subtype. Both direct IMF of skin (perilesional) and indirect IMF using patients’ serum show intercellular staining of IgG within the epidermis.

Clinical features

Mucosal involvement (especially oral ulceration) is common and is the presenting sign in up to 50% of cases. This may then be followed by the appearance of non-itchy flaccid blisters, particularly involving the trunk. Blistering usually becomes widespread but they rapidly denude; thus pemphigus often presents with erythematous, weeping erosions. Blisters can be extended with gentle sliding pressure (Nikolsky’s sign). Flexural lesions often have a vegetative appearance. In pemphigus foliaceus the blisters and erosions often start in a seborrhoeic distribution (scalp, face and upper chest) before becoming more widespread.

FURTHER READING

Groves RW. Pemphigus: a brief review. Clin Med 2009; 9:371–375.

Treatment

This is with very high-dose oral prednisolone (60–100 mg daily) or pulsed methylprednisolone and is often needed lifelong. Therefore other immunosuppressants such as azathioprine or mycophenolate mofetil (or occasionally cyclophosphamide or ciclosporin) are used as steroid-sparing agents. Intravenous immunoglobulin infusions help gain quick control whilst waiting for these other drugs to work. The anti-B cell drug rituximab (anti-CD20 monoclonal antibody) is useful in multidrug-resistant cases.

Whilst treatment is normally effective, perhaps up to 10% of patients may die either due to complications of the disease or more commonly from side-effects of the treatment.

Bullous pemphigoid

Bullous pemphigoid is more common than pemphigus. It presents in later life (usually over 60) and mucosal involvement is rarer. Autoantibodies against a 230 kDa or 180 kDa hemidesmosomal protein (‘bullous pemphigoid antigen 1’ and ‘type XVII collagen’) play an aetiological role.

Skin biopsy shows a deeper blister (than in pemphigus) due to a subepidermal split through the basement membrane. Direct and indirect IMF studies show linear staining of IgG along the basement membrane.

Clinical features

Large tense bullae appear anywhere on the skin but often involve limbs (Fig. 24.28), hands and feet. The bullae may be centred on an erythematous or urticated background and they can be haemorrhagic. Pemphigoid can be very itchy. Mucosal ulceration is uncommon but a variant of pemphigoid exists which predominantly affects mucosal surfaces with scarring (mucous membrane pemphigoid).

image

Figure 24.28 Bullous pemphigoid.

image

Bullous pemphigoid – life-threatening blistering.

Treatment

This is with high-dose oral prednisolone (30–60 mg daily) and steroid-sparing agents such as azathioprine or mycophenolate mofetil. Weekly methotrexate is also occasionally used. In general, disease control is easier than with pemphigus. Often treatment can be withdrawn after 2–3 years. Treatment often causes side-effects, especially as most patients are elderly. Occasionally localized or mild disease can be controlled with superpotent topical steroids, oral dapsone or high-dose oral minocycline.

Dermatitis herpetiformis

Dermatitis herpetiformis (DH) (see also p. 266) is a rare blistering disorder associated with gluten-sensitive enteropathy (coeliac disease). DH and coeliac disease are associated with other organ-specific autoimmune disorders. The HLA associations (B8, DR3, DQ2 in 80–90% of cases) and immunological findings (endomysial, tissue transglutaminase, reticulin and gliadin autoantibodies present in serum) are similar to coeliac disease.

Skin biopsy shows a subepidermal blister with neutrophil microabscesses in the dermal papillae. Direct immunofluorescent studies of uninvolved skin show IgA in the dermal papillae and patchy granular IgA along the basement membrane. The jejunal mucosa shows a partial villous atrophy.

Clinical features

Dermatitis herpetiformis is commoner in males and can present at any age but is most likely to appear for the first time in young adult life. It presents with small, intensely itchy blisters of the skin. The lesions have a predilection for the elbows, extensor forearms, scalp and buttocks. The tops of the blisters are usually scratched off; thus crusted erosions are often seen at presentation. Remissions and exacerbations are common.

Treatment

This should always be with a gluten-free diet (GFD, p. 266). Control of the skin disease can be obtained with oral dapsone (50–200 mg daily) or sulphonamides. If a strict GFD is adhered to, oral medication can often be withdrawn after 2 years.

Use of dapsone. Dapsone frequently causes a mild dose-related haemolytic anaemia (which is usually well tolerated) but the haemolysis can be devastating if there is G6PD deficiency. Liver damage, peripheral neuropathy and aplastic anaemia can also rarely occur so regular monitoring of a blood count and liver function is needed.

Linear IgA disease (chronic bullous dermatosis of childhood)

Linear IgA disease is a subepidermal blistering disorder of adults and children. Pathogenic IgA autoantibodies bind to a variety of basement membrane proteins including type XVII collagen and laminin-332 (see Fig. 24.27). It is the most common immunobullous disease seen in children. Rarely it is induced by vancomycin.

image

Linear IgA disease – typical circular clustering of blisters.

Clinical features

Linear IgA disease can present with circular clusters of large blisters, a pemphigoid type of blistering or a dermatitis herpetiformis picture. Mucosal involvement of the mouth, vulva and eyes is not uncommon and can cause scarring. Direct IMF studies of skin show linear IgA deposition along the basement membrane.

Treatment

This is with oral dapsone (50–200 mg daily) or sulphonamides. Occasionally, immunosuppression is needed. Many patients show spontaneous resolution after 3–6 years.

Mechanobullous disease (epidermolysis bullosa, ‘EB’)

These are due to inherited abnormalities in structural skin proteins which lead to ‘skin fragility’. The resultant blistering tends to arise secondary to trauma and often appears at or shortly after birth. These conditions can be a mild inconvenience, severely disabling or fatal but fortunately are very rare. There are three groups of disorders in which the fundamental gene/protein abnormalities have been characterized.

image Epidermolysis bullosa simplex is a group of autosomal dominant genodermatoses characterized by ‘superficial’ blistering owing to mutations of cytoskeleton proteins within the basal layer of the epidermis, e.g. keratin 5 (chromosome 12q) or keratin 14 (chromosome 17q). Most forms of EB simplex show mild disease with intermittent blistering of the hands and feet, especially in hot weather. The teeth and nails are normal and scarring is absent.

image Epidermolysis bullosa dystrophica is a group of genodermatoses characterized by ‘deeper’ blistering associated with scarring and milia formation. The level of split is deep within the basement membrane and is due to a mutation in the COL-7A1 gene (locus at chromosome 3p21.1) which causes a loss of collagen VII in the anchoring fibrils. Nails, mucosae and even the larynx are often involved. The autosomal dominant variety is milder but the autosomal recessive type produces severe disease with painful disabling scarring, fusion of digits, joint contractures and dysphagia. Life expectancy is significantly reduced. Repeated scarring results in the development of multiple squamous cell carcinomas and most die from this complication in early adult life. The average life expectancy after the appearance of the first squamous cell carcinoma is 5 years. Stem cell transplantation is being used.

image Junctional epidermolysis bullosa is the most severe form. It is characterized by a split in the lamina lucida of the basement membrane and is due to mutations in various proteins, mainly laminin-332 but also α6β4 integrin or type XVII collagen. It presents at birth with widespread blistering and areas of absent skin. Erosions of the central face and hoarseness from laryngeal involvement are common. Nail and teeth abnormalities are also common. Both a lethal and a rarer non-lethal form of junctional EB exist and they show an autosomal recessive inheritance. The lethal form causes death in infancy or early childhood.

FURTHER READING

Uitto J, McGrath JA, Rodeck U et al. Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol 2010; 130:1778–1784.

Wagner JE, Yamamoto AI, McGrath JA et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010; 363:629–639, 680–682.

Investigation and treatment

Investigation and treatment of EB should be carried out in a specialist centre. Exact diagnosis depends on ultrastructural analysis of induced blisters in the skin and immunohistochemistry, and these investigations can be further confirmed with genetic testing. Only then can prognosis and genetic counselling be given accurately to parents. Prenatal diagnosis and preimplantation diagnosis is available for the more severe forms of EB. Gene therapy and bone marrow transplantation are two new approaches that are currently under assessment.

Skin tumours

Benign cutaneous tumours

Melanocytic naevi (moles)

Moles are a benign overgrowth of melanocytes that are common in white-skinned people. They appear in childhood and increase in number and size during adolescence and early adult life. They often start as flat brown macules with proliferation of melanocytes at the dermoepidermal junction (junctional naevi). The melanocytes continue to proliferate and grow down into the dermis (compound naevi) which causes an elevation of the mole above the skin surface. The pigmentation is usually even and the border regular. They eventually mature into a dermal naevus (cellular naevus), often with a loss of pigment.

Blue naevus is an acquired asymptomatic blue-looking mole. It is due to a proliferation of melanocytes deep in the mid-dermis.

Basal cell papilloma (seborrhoeic wart)

This is a common benign overgrowth of the basal cell layer of the epidermis. The lesion can be flesh coloured, brown or even black and often has a greasy appearance. The surface is irregular and warty and the lesions appear very superficial as though stuck on to the skin (Fig. 24.29). Tiny keratin cysts may be seen on the surface. They can be treated with cryotherapy or curettage.

image

Figure 24.29 Seborrhoeic warts (basal cell papillomas).

Dermatofibroma (histiocytoma)

Dermatofibromas appear as firm, elevated pigmented nodules which may feel like a button in the skin. A peripheral ring of pigmentation is sometimes seen. They are often found on the leg and are commoner in females. There may be a preceding history of trauma or insect bite. The lesion consists of histiocytes, blood vessels and varying degrees of fibrosis. If symptomatic, excision is required.

Epidermoid cyst (previously ‘sebaceous cyst’)

Epidermoid cysts present as cystic swellings of the skin with a central punctum. They contain ‘cheesy’ keratin. These cysts occasionally rupture causing significant dermal inflammation.

Pilar cyst (trichilemmal cyst)

Pilar cysts are smooth cysts without a punctum usually found on the scalp. They may be multiple and familial.

Keratoacanthoma

Keratoacanthomas are rapidly growing epidermal tumours which develop central necrosis and ulceration (Fig. 24.30). They occur on sun-exposed skin in later life and can grow up to 2–3 cm across. Whilst they may resolve spontaneously over a few months, they are best excised both to exclude a squamous cell carcinoma (which they can mimic) and to improve the cosmetic outcome.

image

Figure 24.30 Keratoacanthoma.

Pyogenic granuloma (granuloma telangiectaticum)

Pyogenic granulomas are a benign overgrowth of blood vessels. They present as rapidly growing pinkish red nodules which are friable and readily bleed. They may follow trauma and are often found on the fingers and lips. They are best excised to exclude an amelanotic malignant melanoma.

Cherry angioma (Campbell de Morgan spots)

These are benign angiokeratomas that appear as tiny pinpoint red papules, especially on the trunk, and increase with age. No treatment is required.

Potentially pre-malignant cutaneous tumours

Solar keratoses (actinic keratoses)

These frequently develop later in life in white-skinned people who have had significant sun exposure. They appear on exposed skin as erythematous silver-scaly papules or patches with a conical surface and a red base (Fig. 24.31). The background skin is often inelastic, wrinkled and may show flat brown macules (solar lentigos) reflecting diffuse solar damage. A small proportion of these keratoses can transform into squamous cell carcinoma but only after many years.

image

Figure 24.31 Solar keratoses with background actinic damage.

Treatment of lesions is with cryotherapy, topical 5-fluorouracil cream, 5% imiquimod cream or diclofenac gel.

Bowen’s disease

This is a form of intraepidermal carcinoma-in-situ which rarely can become invasive. It is thought to be due to long-term sun exposure. It presents on exposed skin, most commonly women’s legs, as an isolated scaly red patch or plaque looking rather like psoriasis although it has a rather irregular edge. The lesions do not clear but slowly increase in size with time.

A variant which can show partial or full-thickness dysplasia can involve the epidermis of the mucosa or neighbouring skin. This can affect the vulva, the glans penis and perianal skin and is termed vulval (penile, or anal) intraepithelial neoplasia. Clinically, it can present as nonspecific erythema or as a warty thickening. These diseases have a stronger link with HPV and probably have a higher pre-malignant potential than Bowen’s disease. They are commoner in immunosuppressed individuals. The anal form is increasingly reported in HIV-positive patients (as indeed is anal carcinoma) and extension into the rectum may occur.

image

Erythroplasia of glans penis (penile intraepithelial neoplasia).

Treatment is with topical 5-fluorouracil, 5% imiquimod cream, cryotherapy, curettage, photodynamic therapy or a tissue-destructive laser.

Atypical mole syndrome (dysplastic naevus syndrome)

This is often familial. A large number of melanocytic naevi begin to appear in childhood even on unexposed sites. Individual lesions may be large with irregular pigmentation and border, and histologically they may show cytological and architectural atypia but no frank malignant change. Individuals with this condition have an increased risk of developing malignant melanoma. They should have their moles photographed and be regularly reviewed. Suspicious lesions should be excised.

Giant congenital melanocytic naevi

These are very large moles present at birth. Very large lesions (>20 cm across) show an increased risk of developing malignant melanoma (up to 5%). Excision may be considered but is rarely possible without multiple operations and marked disfigurement so regular monitoring is advised. There have been a number of reports showing that a few of these lesions improve spontaneously and partially resolve during childhood.

Lentigo maligna

This is a slow-growing macular area of pigmentation seen in elderly people, commonly on the face. The border and pigmentation are often irregular. Some people regard this lesion as a melanoma-in-situ. There is an increased risk of developing invasive malignant melanoma. Treatment is by excision if possible but 5% imiquimod cream is currently being tried in the very large lesions where surgery would be disfiguring.

Malignant cutaneous tumours

Basal cell carcinoma (rodent ulcer)

Basal cell carcinomas (BCC) are the most common malignant skin tumour but their relationship to excessive sun exposure is complex. Genotype and phenotype of the patient is also involved in pathogenesis. Multiple BCCs are seen in Gorlin’s syndrome due to mutations in the PTCH1 gene and mutations in this gene have also been described in the sporadic form of BCC.

BCCs are common later in life on exposed sites although rare on the ear. They are 10–20 times more common in the chronically immunosuppressed solid organ transplant population. They can present as a slow-growing papule or nodule (or rarely be cystic), which may go on to ulcerate (Fig. 24.32). Telangiectasia over the tumour or a skin-coloured jelly-like ‘pearly edge’ may be seen. A flat, diffuse superficial form exists as an ill-defined ‘morphoeic’ variant. Basal cell carcinomas will slowly grow and erode structures if untreated but these tumours almost never metastasize.

image

Figure 24.32 Ulcerating basal cell carcinoma.

Treatment

Treatment is usually with surgical excision with controlled borders. Photodynamic therapy, cryotherapy, 5% imiquimod cream and rarely radiotherapy can be useful for large superficial forms but follow-up for recurrence is required. Curettage may occasionally be used in older patients although not for central facial lesions as they often recur. Recurrent tumour or morphoeic basal cell carcinoma is best treated with Mohs’ micrographic surgery to ensure adequate clearance.

Squamous cell carcinoma

Squamous cell carcinoma (SCC) is a more aggressive tumour than basal cell carcinoma as it can metastasize if left untreated. Most relate directly to sun exposure, and daily application of sun cream has been shown to reduce the incidence in Australia. SCC can arise in pre-existing solar keratoses or Bowen’s disease or be due to chronic inflammation such as in lupus vulgaris. Rarely multiple tumours may arise due to arsenic ingestion in early life. Multiple tumours also occur in people who have had prolonged periods of immunosuppression such as renal transplant patients where certain human papilloma virus subtypes may be involved in malignant transformation.

Clinically, the lesions are often keratotic, rather ill-defined nodules which may ulcerate (Fig. 24.33). They can grow very rapidly. Examination of regional lymph nodes is essential. They are most common on sun-exposed sites in later life. Ulcerated lesions on the lower lip or ear are often more aggressive.

image

Figure 24.33 Squamous cell carcinoma.

Treatment

Treatment is with excision or occasionally radiotherapy. Curettage should be avoided.

FURTHER READING

Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010; 375:673–685.

Malignant melanoma

Malignant melanoma is the most serious form of skin cancer as metastasis can occur early and it causes a number of deaths even in young people. As with other types of skin cancer the incidence is continuing to increase, probably due to excessive exposure to sunlight. The history of childhood sun exposure and intermittent intense sun exposure appears to be necessary for the development of malignant melanoma. Other risk factors include pale skin, multiple melanocytic naevi (>50), sun sensitivity, immunosuppression, atypical mole syndrome, giant congenital melanocytic naevi, lentigo maligna and a positive family history of malignant melanoma. Malignant melanoma is commoner in later life but many young adults are also affected. A number of oncogenes and tumour suppressor proteins (CDK4, CDKN2a, B-RAF, PTEN, Ras, Rb, p53, p16) have been implicated in the pathogenesis of melanoma. Some 60% of human melanomas have an activating mutation (V600E) in the serine protein kinase B-RAF which has now become a target for ‘personalized’ therapy(p. 1226).

Diagnosis of melanoma is not always easy but the clinical signs listed in Table 24.13 help distinguish malignant from benign moles. Examination with a dermatoscope (a handheld polarized light source with magnification) can further help in detecting malignant lesions.

Table 24.13 Clinical criteria for the diagnosis of malignant melanoma

ABCDE criteria (USA):

Asymmetry of mole

Border irregularity

Colour variegation

Diameter >6 mm

Elevation

The Glasgow 7-point checklist:

Major criteria

Change in size

Change in shape

Change in colour

Minor criteria

Diameter >6 mm

Inflammation

Oozing or bleeding

Mild itch or altered sensation

Four clinical types exist:

image Lentigo maligna melanoma is where a patch of lentigo maligna develops a papule or nodule signalling invasive tumour.

image Superficial spreading malignant melanoma is a large flat irregularly pigmented lesion which grows laterally before vertical invasion develops.

image Nodular malignant melanoma (Fig. 24.34) is the most aggressive type. It presents as a rapidly growing pigmented nodule which bleeds or ulcerates. Rarely they are amelanotic (non-pigmented) and can mimic pyogenic granuloma.

image Acral lentiginous malignant melanomas arise as pigmented lesions on the palm, sole or under the nail and they usually present late. They may not be related to sun exposure.

image

Figure 24.34 Nodular malignant melanoma.

FURTHER READING

Smalley KS, Sondak VK. Melanoma – an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363:876–878, 809–819.

Treatment

In the UK, all people with melanoma >1 mm thick should be referred to their regional multidisciplinary team for expert management. Surgery is the only curative treatment: urgent wide excision 1 cm margin for thin melanomas (<1 mm) increasing to 3 cm margin for thicker melanomas (>2 mm). Histological analysis will determine the depth of invasion (‘Clark’s level’) and the thickness of the tumour (‘Breslow thickness’). People with thick melanomas are staged according to the American AJCC 2009 criteria which look at tumour thickness, metastasis and lymph node status and this helps predict prognosis and 5-year survival rates. Sentinel node biopsy for people with thicker lesions is currently under assessment as a tool for predicting prognosis, determining therapy (e.g. lymph node dissection) and improving survival but it remains a research tool. Metastatic disease can involve surgery to lymph nodes, isolated limb perfusion, radiotherapy, immunotherapy and chemotherapy but no therapy in phase 3 trials has yet shown a significant increase in survival. Ipilimumab is showing early promise in selected people with metastatic disease. Vemurafenib is a potent kinase inhibitor with specificity for the BRAF V600E metastatic melanoma; 50% of patients respond, with an overall survival of 16 months.

FURTHER READING

Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncology 2009; 27:6199–6206.

Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–723, 779–781.

Sosman JA et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707–714.

Cutaneous T cell lymphoma (mycosis fungoides)

This is a rare type of skin tumour which often follows a relatively benign course. It presents insidiously with scaly patches and plaques which can look eczematous or psoriasiform. Lesions often appear initially on the buttocks. These lesions may come and go or remain persistent over many years. Patients may well die of unrelated causes. Skin biopsy confirms the diagnosis, showing invasion by atypical lymphocytes. T cell receptor gene rearrangement studies show that there is often a monoclonal expansion of lymphocytes in the skin.

image

Patch stage mycosis fungoides.

Occasionally the disease can progress to a cutaneous nodular or tumour stage, which may be accompanied by systemic organ involvement. In elderly males the disease may progress rarely to an erythrodermic variant accompanied by lymphadenopathy and peripheral blood involvement (‘Sézary’s syndrome’).

All patients should be staged at the time of diagnosis to assess for any systemic involvement.

Treatment

Early cutaneous disease can be left untreated or treated with topical steroids or PUVA. More advanced disease of the skin, or systemic involvement, may require radiotherapy, oral retinoids (bexarotene), chemotherapy (e.g. methotrexate), immunotherapy or electron beam therapy. AntiCD4 and antiCD25 monoclonal antibodies are currently under assessment in advanced disease.

FURTHER READING

Hwang ST, Janik JE, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371:945–957.

Kaposi’s sarcoma

This is a tumour of vascular and lymphatic endothelium that presents as purplish nodules and plaques. There are three types:

image Theclassicor ‘sporadicform (as described by Kaposi) occurs in elderly males, especially Jewish people from Eastern Europe. It presents as slow-growing purple tumours in the foot and lower leg which rarely cause any significant problem.

image Theendemicform occurs in males from central Africa and shows more widespread cutaneous involvement as well as lymph node (or occasionally systemic) involvement. Oedema is a prominent feature.

image The immunosuppression-related form is more severe and is most common in HIV-positive men who have sex with men. Lesions are widespread and often affect the skin, bowel, oral cavity and lungs.

All three types have a strong association with herpes virus type 8 but other factors must be involved as herpes type 8 seroprevalence is up to 10% in the USA and 50% in some African countries. HAART (p. 171) has significantly reduced the incidence of Kaposi’s sarcoma in HIV infection although the prevalence has started to increase again over the last few years for as yet unexplained reasons.

FURTHER READING

Bergan JJ, Schmid-Schönbein GW, Smith PD et al. Chronic venous disease. N Engl J Med 2006; 355:488–498.

Treatment

Treatment of advanced Kaposi’s sarcoma is with radiotherapy, immunotherapy or chemotherapy.

Disorders of blood vessels/lymphatics

Leg ulcers

Leg ulcers are common and can have many causes (Table 24.14). Venous ulcers are the most common type in developed countries.

Table 24.14 Causes of leg ulceration

Venous hypertension

Arterial disease (e.g. atherosclerosis)

Neuropathic (e.g. diabetes, leprosy)

Neoplastic (e.g. squamous or basal cell carcinoma)

Vasculitis (e.g. rheumatoid arthritis, SLE, pyoderma gangrenosum)

Infection (e.g. ecthyma, tuberculosis, deep mycoses, Buruli ulcer, syphilis, yaws)

Haematological (e.g. sickle cell disease, spherocytosis)

Drug (e.g. hydroxycarbamide (hydroxyurea))

Other (e.g. necrobiosis lipoidica, trauma, artefact)

Venous ulcers

Venous ulcers are the result of sustained venous hypertension in the superficial veins, owing to incompetent valves in the deep or perforating veins or to previous deep vein thrombosis. The increased pressure causes extravasation of fibrinogen through the capillary walls, giving rise to perivascular fibrin deposition, which leads to poor oxygenation of the surrounding skin.

Venous ulcers are common in later life and cause a significant drain on healthcare budgets as they are often chronic and recurrent; they affect 1% of the population over the age of 70 years. They are most commonly found on the lower leg in a triangle above the ankles (Fig. 24.35), and may be associated with:

image Oedema of the lower legs

image Venous eczema (p. 1206)

image Brown pigmentation from haemosiderin

image Varicose veins

image Lipodermatosclerosis (the combination of induration, reddish brown pigmentation and inflammation) – a fibrosing panniculitis of the subcutaneous tissue

image Scarring white atrophy with telangiectasia (atrophie blanche).

image

Figure 24.35 Venous leg ulcer.

Treatment is with high-compression bandaging (e.g. four-layer bandaging) and leg elevation to try to decrease the venous hypertension. Doppler studies should always be done before bandaging to exclude arterial disease. This treatment is best delivered in the community by appropriately trained nurses. Ulcer dressings are used to keep the ulcer moist and free of slough and exudates. Up to 80% of ulcers can be healed within 26 weeks. Slower healing rates occur in patients who have decreased mobility and if the ulcers are very large, present for longer than 6 months or bilateral. Diuretics are sometimes helpful to reduce the oedema. Antibiotics are necessary only for overt bacterial infection.

Venous leg ulcers can be very painful so adequate analgesia should be given, including opiates if required. Split-thickness skin grafting is used in resistant cases. Support stockings (individually fitted) should be worn lifelong after healing as this lessens recurrence.

Underlying venous disease is best investigated with duplex ultrasound or plethysmography. Therapeutic ultrasound is now proven not to help ulcer healing. Surgery for purely superficial venous disease does not help ulcer healing but it is proven to help prevent ulcer recurrence (ESCHAR study).

Arterial ulcers

Arterial ulcers present as punched-out, painful ulcers higher up the leg or on the feet. There may be a history of claudication, hypertension, angina or smoking. Clinically, the leg is cold and pale. Absent peripheral pulses, arterial bruits and loss of hair may be present. Doppler ultrasound studies will confirm arterial disease.

Treatment depends on keeping the ulcer clean and covered, adequate analgesia and vascular reconstruction if appropriate. Compression bandaging must not be used.

Neuropathic ulcers

Neuropathic ulcers tend to be seen over pressure areas of the feet, such as the metatarsal heads, owing to repeated trauma. These are most commonly seen in diabetics due to peripheral neuropathy. In some developing countries leprosy is a common cause.

Treatment depends on keeping the ulcer clean and removing pressure or trauma from the affected area. Diabetics should pay particular attention to foot care and correctly fitting shoes with the help of a specialist podiatrist (p. 1009).

SIGNIFICANT WEBSITES

NICE UK guidelines on pressure sores:

http://guidance.nice.org.uk/CGB (Risk assessment and prevention).

http://guidance.nice.org.uk/CG29 (Management)

FURTHER READING

Gohel MS, Barwell JR, Taylor M et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 2007; 335(7610):83.

Watson J, Kang’ombe A, Soares M et al. VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers. Health Technol Assess 2011; 15:1–176.

Pressure sores (decubitus ulcers, bedsores)

These occur in the elderly, immobile, unconscious or paralysed patients. They are due to skin ischaemia from sustained pressure over a bony prominence, most commonly the heel and sacrum. Normal individuals feel the pain of continued pressure, and even during sleep movement takes place to change position continually. Pressure sores may be graded:

image Stage I: non-blanchable erythema of intact skin

image Stage II: partial-thickness skin loss of epidermis/dermis (blister or shallow ulcer)

image Stage III: full-thickness skin loss involving subcutaneous tissue but not fascia

image Stage IV: full-thickness skin loss with involvement of muscle/bone/tendon/joint capsule.

There are numerous risk factors for development of pressure sores (Table 24.15).

Table 24.15 Risk factors for the development of pressure sores

Prolonged immobility

Paraplegia

Arthritis

Severe physical disease

Apathy

Operation and postoperative states

Plaster casts

Intensive care

Decreased sensation

Coma, neurological disease, diabetes mellitus

Drug-induced sleep

Vascular disease

Atherosclerosis, diabetes mellitus, scleroderma, vasculitis

Poor nutrition

Anaemia

Hypoalbuminaemia

Vitamin C or zinc deficiency

The majority of pressure sores occur in hospital. Some 70% appear in the first 2 weeks of hospitalization, and 70% are in orthopaedic patients, especially those on traction. Between 20% and 30% of pressure sores occur in the community. Some 80% of patients who have deep ulcers involving the subcutaneous tissue die in the first 4 months.

The early sign of red/blue discoloration of the skin can lead rapidly to ulcers in 1–2 hours. Leaving patients on hard emergency room trolleys, or sitting them in chairs for prolonged periods, must be avoided.

Management

Prevention

Prevention is better than cure. Specialist ‘tissue-viability nurses’ help identify at-risk patients and train other clinical staff. Several risk assessment tools have been devised for the immobile patient based on the known risk factors. The ‘Norton scale’ and Waterlow Pressure Sore Risk Assessment (Box 24.4) are two such validated systems, which produce a numerical score, enabling staff to identify those at most risk. Braden, Walsall and Maelor scales are also used.

image Box 24.4

Pressure sore risk-assessment tools

image

Treatment

image Bed rest with pillows and fleeces to keep pressure off bony areas (e.g. sacrum and heels) and prevent friction

image Air-filled cushions for patients in wheelchairs

image Special pressure-relieving mattresses and beds

image Regular turning but avoid pressure on hips

image Ensure adequate nutrition

image Non-irritant occlusive moist dressings (e.g. hydrocolloid)

image Adequate analgesia (may need opiates)

image Plastic surgery (debridement and grafting in selected cases)

image Treatment of underlying condition.

Vasculitis

Vasculitis (see also p. 542) is the term applied to an inflammatory disorder of blood vessels which causes endothelial damage. Cutaneous vasculitis (confirmed by skin biopsy) may be an isolated problem but occasionally is associated with vasculitis in other organs. The most commonly used classification is based on the size of blood vessel involved (see Tables 11.19 and 11.20).

The cutaneous features are of haemorrhagic papules, pustules, nodules or plaques which may erode and ulcerate. These purpuric lesions do not blanch with pressure from a glass slide (‘diascopy’). Occasionally, a fixed livedo reticularis pattern may appear which does not disappear on warming. Pyrexia and arthralgia are common associations even in the absence of significant systemic involvement. Other clinical features depend on the underlying cause.

Leucocytoclastic vasculitis (LCV) or angiitis is the most common cutaneous vasculitis affecting small vessels. This usually appears on the lower legs as a symmetrical palpable purpura. It is rarely associated with systemic involvement. It can be caused by drugs (15%), infection (15%), inflammatory disease (10%) or malignant disease (<5%) but often no cause is found (55–60%). Investigations are only necessary with persistent lesions or associated signs and symptoms. Whilst LCV often settles spontaneously, treatment with analgesia, support stockings, dapsone or prednisolone may be needed to control the pain and to heal up any ulceration. Urticarial vasculitis is discussed on page 1211.

Calciphylaxis (calcific uraemic arteriopathy) is described in Chapter 12.

Lymphatics

Lymphoedema

Lymphoedema refers to a chronic non-pitting oedema due to lymphatic insufficiency. It is most commonly seen affecting the legs and tends to progress with age. The legs can become enormous and prevent wearing of normal shoes. Chronic disease may cause a secondary ‘cobblestone’ thickening of the skin. Lymphoedema can be primary (and present early in life) due to an inherited deficiency of lymphatic vessels (e.g. Milroy’s disease) or can be secondary due to obstruction of lymphatic vessels (e.g. filarial infection or malignant disease).

Treatment is with compression stockings and physical massage. If there is recurrent cellulitis, long-term antibiotics are advisable as each episode of cellulitis will further damage the lymph vessels. Surgery should be avoided.

Lymphangioma circumscriptum

This is a rare hamartoma of lymphatic tissue. It usually presents in childhood with multiple small vesicles in the skin which weep lymphatic fluid and sometimes blood. They reflect deeper vessel involvement so surgery should be avoided. Cryotherapy or CO2 laser treatment may help the superficial lesions.

Disorders of collagen and elastic tissue

Ehlers–Danlos syndrome (see also p. 559)

Ehlers–Danlos syndrome (EDS) can be subdivided into at least 10 variants. They are all inherited disorders causing abnormalities in collagen of the skin, joints and blood vessels. Clinically this causes increased elasticity of the skin, hypermobile joints (6–9 on the Beighton scale; see Box 11.19) and fragile blood vessels causing easy bruising or in some cases internal haemorrhage. The skin is hyperextensible but recoils normally after stretching. It is easily injured and heals slowly with scarring like tissue paper. Pseudotumours may occur at the sites of scarring (such as elbows and knees) consisting mainly of fat, but calcification can occur.

Pseudoxanthoma elasticum

Pseudoxanthoma elasticum is a rare disease characterized by abnormal mineralization of collagen and elastic tissue primarily affecting the skin, eye and blood vessels. It is caused by mutations in the cell transporter gene ABCC6. The phenotype can vary enormously and this may be dependent on the site of the mutation. The skin may be loose, lax and wrinkled. It can look yellowish and papular (‘plucked chicken skin’) and tends to lose its elastic recoil when stretched. Skin changes are best seen in the flexures, especially the sides of the neck. Non-cutaneous features are not always present but they include recurrent gastrointestinal bleeding, early myocardial infarction, claudication and angioid streaks on the retina reflecting disruption of vascular elastic tissue.

FURTHER READING

Larusso J, Ringpfeil F, Uitto J. Pseudoxanthoma elasticum: a streamlined ethnicity-based mutation detection strategy. Clin Transl Sci 2010; 3:295–298.

Li Q, Sadowski S, Uitto J. Angioid streaks in pseudoxanthoma elasticum: role of the p.R1268Q mutation in the ABCC6 gene. J Invest Dermatol 2011; 131:782–785.

Striae

Striae are visible linear scars due to dermal collagen damage and stretching. Histologically a thinned epidermis overlies parallel bundles of fine collagen. They occur commonly over the abdomen and breasts in pregnancy but also occur on the thighs and trunk in rapidly growing adolescents as well as in some obese individuals. They are also seen in Cushing’s syndrome and corticosteroid therapy. They are also rarely seen in Marfan’s syndrome. Striae are initially reddish blue but fade to white atrophic marks. Puberty-related striae normally disappear completely.

Keloid scars

Keloid scars are characterized by smooth hard nodules (Fig. 24.36) due to excessive collagen production. They may occur spontaneously or follow skin trauma/surgery and they are often itchy. They tend to affect young adults and are much commoner in black Africans. Sites of predilection include the shoulders, upper back and chest, earlobes and chin. Unlike hypertrophic scars (which fade within 12 months) keloids are persistent and may continue to enlarge.

image

Figure 24.36 Keloid scar of the lobe of the ear.

Treatment is with triamcinolone injection, compression with silica gels or surgery, but surgery must be followed by steroid injection or superficial radiotherapy or it may make the problem worse.

FURTHER READING

Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25:26–32.

Disorders of pigmentation

Hypopigmentation

Vitiligo

Vitiligo is a common autoimmune disorder of depigmentation due to areas of melanocyte loss. Sufferers often have relatives with other organ-specific autoimmune disorders. It presents in childhood or early adult life with well-demarcated macules of complete pigment loss. There is no history of preceding inflammation. Patients are very susceptible to sunburn. Lesions are often symmetrical and frequently involve the face, hands and genitalia (Fig. 24.37). The hair can also depigment. Trauma may induce new lesions. Spontaneous repigmentation can occur and often starts around hair follicles, giving a speckled appearance. However, repigmentation is rare if a lesion has persisted for more than 1 year or if the hair is depigmented.

image

Figure 24.37 Vitiligo of the hands showing areas of depigmentation.

Treatment is often unsatisfactory and has no impact on the long-term outcome. Sunblocks should be used to prevent burning. Potent topical steroids or phototherapy may help some individuals. Tacrolimus ointment (0.1%) can be a useful therapy in some individuals, especially on the face. If vitiligo is almost universal and fixed, depigmentation with monobenzone can be used. Finally, referral to a specialist camouflage clinic is often the most helpful ‘treatment’.

FURTHER READING

Jin Y, Birlea SA, Fain PR et al. Variant of TYR and autoimmune susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686–1697.

Taïcb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360:160–169.

Whitton ME, Ashcroft DM, Barrett CW et al. Interventions for vitiligo. Cochrane Database Syst Rev 2006; 25:CD003263.

Post-inflammatory hypopigmentation

This is one of the most common causes of pale skin. It is much more common in people with pigmented skin. It may be seen as a consequence of eczema, acne or psoriasis and may even be the reason for individuals presenting to a doctor. Providing the skin disease is controlled the pigmentation will recover slowly after many months. Post-inflammatory hyperpigmentation can also occur.

Oculocutaneous albinism

This is a group of rare autosomal recessive disorders affecting the pigmentation of skin, hair and eyes. It can affect all races. Melanocytes are normal in number but have abnormal function. Clinically it presents with universal pale skin, white or yellow hair and a pinkish iris. Photophobia, nystagmus and a squint are also present in most cases.

Treatment involves obsessive protection against sunlight to avoid sun burning and development of skin cancer.

Idiopathic guttate hypomelanosis

This occurs most commonly in black African people and is of unknown aetiology. It presents with small (2–4 mm) asymptomatic porcelain-white macules, often on skin exposed to sunlight. The borders are often sharply defined and angular. There is no effective treatment.

Leprosy (see also p. 130)

Both tuberculoid leprosy and indeterminate leprosy can present with anaesthetic patches of depigmentation and should always be considered in people from endemic regions. Loss of hair and decreased sweating may also be present in the lesions.

Hyperpigmentation

Freckles (ephelides)

These appear in childhood as small brown macules after sun exposure. They fade in the winter months.

Lentigos

These are a more permanent macule of pigmentation similar to freckles but they tend to persist in the winter. Solar lentigos (also called ‘liver spots’) occur in older people on exposed skin due to actinic damage.

Chloasma (melasma)

These are brown macules often seen symmetrically over the cheeks and forehead and are most common in women. Chloasma can occur spontaneously but it is also associated with pregnancy and the oral contraceptive pill.

Metabolic/endocrine effects

A generalized skin darkening can occur with chronic liver disease, especially haemochromatosis. It also is seen sometimes in Cushing’s syndrome, Addison’s disease (more marked in palmar creases and buccal mucosa) and Nelson’s syndrome.

Peutz–Jeghers syndrome (p. 271)

This is an autosomal dominant condition which presents with brown macules of the lips and perioral region. It is associated with gastrointestinal polyposis.

Urticaria pigmentosa (cutaneous mastocytosis)

This presents most commonly with multiple pigmented macules in children. These lesions tend to become red, itchy and urticated if they are rubbed (Darier’s sign). Occasionally lesions may blister, and in the rare congenital, diffuse form of the disease the skin may become thickened and leathery. Occasionally systemic symptoms are present such as wheeze, flushing, syncope or diarrhoea, reflecting extensive mast cell degranulation from the skin. Anaphylaxis occurs very rarely and may be precipitated by mast cell degranulators such as aspirin or opiates. The condition spontaneously resolves after some years in children but is persistent in adults.

Skin biopsy shows an excess of mast cells in the skin. A mutation in the proto-oncogene c-kit often underlies the condition resulting in mast cell proliferation and mast cell apoptosis. Rarely there may be infiltration of internal organs with mast cells (systemic mastocytosis), especially in adult disease or neonatal disease. This can involve any organ but especially the bone (where it can cause severe pain), gastrointestinal tract, liver and spleen. There is a small risk of developing leukaemia if the bone marrow is heavily infiltrated.

Treatment of the skin, if required, is with antihistamines, sodium cromoglicate or PUVA as well as avoidance of opiates and NSAIDs.

Other conditions with pigmentation

Café-au-lait macules are seen in neurofibromatosis types 1 and 2, tuberous sclerosis, ataxia telangiectasia, Fanconi’s anaemia, multiple endocrine neoplasia type 1 and McCune–Albright syndrome.

Multiple lentigines are seen in Peutz–Jeghers syndrome, xeroderma pigmentosum, LEOPARD syndrome (Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormalities of genitalia, Retardation of growth, Deafness) and Carney complex (lentiginosis, myxomas of heart and skin, endocrine overactivity).

Acquired melanocytic naevi are seen in Turner’s syndrome (p. 978) and atypical mole syndrome (dysplastic naevus syndrome, p. 1224).

Drug-induced rashes

Drugs can be toxic and teratogenic but they can also cause problems through allergic reactions. This frequently presents in the skin where just about any type of skin rash can arise (Table 24.16) although a widespread symmetrical maculopapular rash is the most common type (Fig. 24.38). ‘Fixed drug eruptions’ occur where a rash evolves and resolves at a specific site. The rash is reproduced at exactly the same site after a repeated exposure.

Table 24.16 Morphological types of drug rashes and some common causes

Maculopapular

Penicillin/amoxicillin

Urticaria

Penicillin, aspirin

Vasculitis

Gold, hydralazine

Fixed drug rash

Phenolphthalein in laxatives, tetracyclines, paracetamol

Pigmentation

Minocycline (black), amiodarone (slate grey)

Lupus erythematosus

Penicillamine, isoniazid

Photosensitivity

Thiazides, chlorpromazine, sulphonamide, amiodarone

Pustular

Carbamazepine

Erythema nodosum

Sulphonamide, oral contraceptive

Erythema multiforme

Barbiturates, etravirine

Acneiform

Corticosteroids

Lichenoid

Chloroquine, thiazides, gold, allopurinol

Psoriasiform

Methyldopa, gold, lithium, beta-blockers

Toxic epidermal necrolysis

Penicillin, co-trimoxazole, carbamazepine, NSAIDs, nevirapine, efavirenz

Pemphigus

Penicillamine, ACE inhibitors

Erythroderma

Gold, sulfonylureas, allopurinol, nevirapine, efavirenz

image

Figure 24.38 Morbilliform drug rash due to penicillin allergy.

The history is of great value in assessing drug reactions as a drug cause is very common. The use of prick testing and patch testing is rarely helpful and not without risk. Drug allergy can only be proven by rechallenging but this is rarely justified as it carries some risks. Rechallenging is occasionally justified for antituberculosis drugs or antiretroviral drugs but this should be carried out under medical supervision as there is a risk of anaphylaxis. Certain individuals (e.g. those with HIV infections) are more susceptible to drug rashes (Fig. 24.39).

image

Figure 24.39 Erythema nodosum in a patient with HIV on co-trimoxazole.

Most rashes will settle spontaneously once the offending agent is removed. The commonest culprits in a hospital setting are antibiotics and chemotherapy agents. The three most serious types of drug rashes are:

image Erythroderma (p. 1215)

image Toxic epidermal necrolysis

image Drug-induced hypersensitivity syndrome.

FURTHER READING

Eshki M, Allanore L, Musette P et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2009; 145:67–72.

Toxic epidermal necrolysis

This is characterized by widespread subepidermal blistering and sloughing of more than 30% of the skin and a high mortality (30–50%). A prodrome of cough, myalgia and anorexia may precede skin signs by 2–3 days. The skin may be itchy but typically takes on a burning quality. Fever and mucosal involvement are common. The internal epithelial surfaces (lung, bladder, gastrointestinal tract) are also involved. Multiorgan failure and sepsis often occur. Toxic epidermal necrolysis (TEN) can be fatal even after drug withdrawal and intensive care support. Patients should be managed in intensive care or a specialized burns unit. All drugs where possible should be withdrawn. Occlusive cutaneous dressings significantly reduce the pain, and an ophthalmological assessment and oral hygiene are necessary. Specific medical treatment with steroids or ciclosporin is controversial and rarely used. Intravenous immunoglobulin may be beneficial if given early in the disease and this is more commonly used.

A variant exists called Stevens–Johnson syndrome (SJS) where the damage is restricted to the mucosal surfaces with milder bullous involvement of the skin (<10%). Both SJS and TEN are commoner in slow acetylators and very much commoner in those with HIV infection.

FURTHER READING

Nagy N, McGrath JA. Blistering skin diseases: a bridge between dermatopathology and molecular biology. Histopathology 2010; 56:91–99.

Drug-induced hypersensitivity syndrome (DHS)

Also called ‘anticonvulsant hypersensitivity syndrome’, ‘drug reaction with eosinophilia and systemic symptoms’, this is a serious adverse systemic reaction to a drug typically occurring 2–6 weeks after initial exposure. It is characterized by a generalized mucocutaneous rash, fever and lymphadenopathy with variable arthralgia, pharyngitis, periorbital oedema and hepatosplenomegaly. Rarely pustulation of the skin and conjunctivitis are present. The blood may show a peripheral eosinophilia, lymphocytosis with atypical lymphocytes, and a hepatitic picture. It can progress to multiorgan failure.

The cause of DHS is unknown but it may in part be due to genetic deficiency of epoxide hydrolase, a hepatic enzyme that detoxifies the arene oxide metabolites of antiepileptic drugs. There have been a number of reports about reactivation of various herpes family viruses (HHV 6 and 7, CMV, EBV) associating with DHS, the significance of which remains unclear. DHS can occur with any drug but a common culprit is one of the aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital, primidone and clonazepam) and as they can cross-react all these drugs must be avoided in the future. Sodium valproate is a suitable alternative. There is also potential for cross-reaction with the newer anticonvulsants vigabatrin and lamotrigine. Treatment is with drug withdrawal, systemic steroids and supportive care.

Disorders of nails

Psoriasis and fungal nail infection are the commonest causes of nail dystrophy and are discussed above.

image Nail pitting can be caused by psoriasis, alopecia areata and atopic eczema. A few pits can be present due to trauma.

image Onycholysis (distal nail plate separation) is caused by psoriasis, thyrotoxicosis, following trauma and rarely due to a photosensitive reaction to drugs such as tetracyclines.

image Koilonychia (thin spoon-shaped nails) can be caused by iron deficiency anaemia or rarely be congenital.

image Leuconychia (white nails) is seen in hypoalbuminaemia. A striate congenital leuconychia exists.

image Beau’s lines (transverse lines) appear as solitary depressions which grow out slowly over many months. They arise due to a severe illness or shock which causes a temporary arrest in nail growth.

image Yellow-nail syndrome is a rare disorder of lymphatic drainage. It presents with thickened, slow-growing, yellow nails which may be associated with pleural effusions, bronchiectasis and lymphoedema of the legs.

image Onychogryphosis is a gross thickening of the nail which is seen in later life, especially in the big toe-nail. There is often a history of preceding trauma. Both psoriasis and fungal infection can also cause nail thickening.

image Nail-patella syndrome is an autosomal dominant condition which presents with triangular rather than half-moon-shaped lunulae, especially of the thumb and forefingers. The nail plates may be small or dystrophic. The patellae are hypoplastic or absent. Other skeletal anomalies may be present and renal impairment (glomerulonephritis) occurs in up to 30% of individuals.

image Melanonychia (longitudinal brown streaks) may be seen as a normal variant in black-skinned patients. In a white patient, it may reflect an underlying subungual melanoma, especially if the pigmentation progresses proximally onto the nail fold (‘Hutchinson’s sign’).

image Clubbing is discussed in Chapter 15.

FURTHER READING

Numerous authors and articles on nail disease. Dermatol Clin 2006; 24(3):297–399.

Disorders of hair

Hair loss

Hair loss can be due to a disorder of the hair follicle in which the scalp skin looks normal (non-scarring alopecia) or due to a disorder within the scalp skin that causes permanent loss of the follicle (scarring or cicatricial alopecia). This latter form causes shiny atrophic bald areas in the scalp which are devoid of follicular openings. There are many causes of alopecia (Table 24.17).

Table 24.17 Causes of alopecia

Scarring alopecia Non-scarring alopecia

Discoid lupus erythematosus

Kerion (tinea capitis)

Lichen planus

Dissecting cellulitis

X-irradiation

Idiopathic (‘pseudopelade’)

Androgenic alopecia

Telogen effluvium

Alopecia areata

Trichotillomania (self-induced hair-pulling)

Tinea capitis

Traction alopecia

Metabolic (iron deficiency, hypothyroidism)

Drug (e.g. heparin, isotretinoin, chemotherapy)

Androgenic alopecia

Androgenic alopecia (male pattern baldness) is the most common type of non-scarring hair loss and depends on genetic factors and an abnormal sensitivity to androgens. It presents in young men with frontal receding followed by thinning of the crown, and there is often a positive family history. It also occurs in females but tends to occur at a later age, be milder and show little in the way of frontal recession. If acne and menstrual disturbance are also present, the cause may be polycystic ovary syndrome or another endocrine disorder of androgens.

Treatment may not be required. Topical 5% minoxidil lotion or oral finasteride (1 mg daily) can help arrest progression and may cause a small amount of regrowth, providing it is used early in disease, but the treatment needs to be continued possibly lifelong. Approximately one-third of patients will not respond to either therapy. Finasteride is a selective inhibitor of 5α-reductase type II and it can cause side-effects in 1% of patients such as loss of libido. It should not be used in females as it can affect the sexual development of a male fetus. However, antiandrogen therapy (e.g. cyproterone acetate or spironolactone) may help some women.

Alopecia areata

Alopecia areata may be regarded as an immune-mediated type of hair loss associated with other organ-specific autoimmune diseases. It presents in children or young adults with patches of baldness (Fig. 24.40). These may regrow to be followed by new patches of hair loss. The presence of broken exclamation mark hairs (narrow at the scalp and wider and more pigmented at the tip) at the edge of a bald area is diagnostic. Regrowth may initially be with white hairs and often occurs slowly over months. Occasionally all of the scalp hair is lost (alopecia totalis) and rarely all body hair is lost (alopecia universalis). The nails may be pitted or roughened.

image

Figure 24.40 Alopecia areata.

Treatment has no effect on the long-term progression. Potent topical or injected steroids may be of limited use. Topical immunotherapy with diphencyprone, PUVA or topical 5% minoxidil is occasionally tried but often does not help. Wigs can be provided for severe cases and patient support groups are often beneficial.

FURTHER READING

Harries MJ, Sinclair RD, Macdonald-Hull S et al. Management of primary cicatricial alopecias: options for treatment. Br J Dermatol 2008; 159:1–22.

Mella JM, Perret MC, Manzotti M et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archi Dermatol 2010; 146:1141–1150.

Wasserman D, Guzman-Sanchez DA, Scott K et al. Alopecia areata. Int J Dermatol 2007; 46:121–131.

Other disorders

Traction alopecia

This refers to the ‘mechanical damage’ type of hair loss that arises from pulling the hair back into a bun or tight plaiting. It is more common in black Africans.

Telogen effluvium

Telogen effluvium refers to the pattern of diffuse hair loss that occurs some 3 months after pregnancy or a severe illness. It occurs because ‘stress’ puts all the hairs into the telogen phase of hair shedding at the same time. The hair fully recovers and the normal staggered hair growth/hair shedding cycle resumes within a few months.

Dissecting cellulitis

This is a chronic folliculitis affecting predominantly young black males. It presents with papules and pustules over the occipital region of the scalp with hair loss. If severe, the back of the scalp becomes a boggy swelling (discharging pus) with areas of scarring alopecia. It can be complicated by keloid scar formation (‘acne keloidalis nuchae’).

image

Dissecting cellulitis of scalp in an African Caribbean male.

Treatment is difficult but prolonged courses of low-dose antibiotics are worth trying in early disease. Prolonged courses of isotretinoin can help a few individuals and deep surgical excision can be used in recalcitrant cases. Combined rifampicin and clindamycin (both 300 mg × 2) can be used in resistant cases.

Increased hair growth – hirsutism

Hirsutism (p. 979) refers to the male pattern of hair growth seen in females. The racial variation in hair growth must be considered. Certain races (e.g. Mediterranean and Asian) have more male pattern hair growth than northern European females. This is not due to excess androgens but may reflect a genetically determined altered sensitivity to them. If virilizing features (deep voice, clitoromegaly, dysmenorrhoea, acne) are present, a full endocrine assessment is necessary. Hirsutism can cause severe psychological distress in some individuals.

Treatment involves physical methods such as bleaching, waxing, electrolysis, photoepilation and laser therapy. Anti-androgen therapy is occasionally helpful.

Hypertrichosis

Hypertrichosis refers to the state of excessive hair growth at any site and occurs in both sexes. It can be seen in anorexia nervosa, porphyria cutanea tarda and underlying malignancy, and is caused by certain drugs (e.g. ciclosporin, minoxidil).

Birth marks/neonatal rashes

Infantile haemangioma (strawberry naevus, cavernous haemangioma)

Infantile haemangioma affects up to 1% of infants. It presents at, or shortly after birth as a single red lumpy nodule that grows rapidly for the first few months. Multiple lesions can be present. They will spontaneously resolve with good cosmesis but may take up to 7 years for complete resolution. Occasionally plastic surgery is needed after resolution to remove residual slack skin. Reassurance of parents is usually all that is required.

image

Strawberry naevus (cavernous haemangioma).

Urgent treatment is indicated if:

image the lesion interferes with feeding or vision

image the lesion ulcerates or bleeds frequently

image the lesion is associated with high-output cardiac failure from shunting of large volumes of blood

image the lesion consumes platelets and/or clotting factors causing potentially life-threatening haemorrhage (‘Kasabach–Merritt syndrome’).

The last two complications are very rare and only tend to occur in large lesions with significant deep vessel involvement.

Treatment has been revolutionized by the discovery in France that oral propranolol (2 mg/kg per day in 3 divided doses) rapidly shrinks these haemangiomas even the deep or sub-glottic lesions. High-dose systemic steroids, vincristine or embolization are rarely used for non-responding patients.

FURTHER READING

Bagazgoitia L, Torrelo A, Gutiérrez JC et al. Propranolol for infantile hemangiomas. Pediatr Dermatol 2011; 28:108–114.

Harper J, Oranje A, Prose N, eds. Textbook of Pediatric Dermatology, 2nd edn. Oxford: Blackwell Scientific; 2006.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649–2651.

Port-wine stain (naevus flammeus)

Port-wine stain is also called a capillary haemangioma but strictly speaking it is not a haemangioma, just an abnormal dilation of dermal capillaries. It presents at birth as a flat red macular area and is commonly found on the face. It does not improve spontaneously and it may become thickened with time. If the lesion is found in the distribution of the first division of the trigeminal nerve it may be associated with ipsilateral meningeal vascular anomalies that can cause epilepsy and even hemiplegia (Sturge–Weber syndrome). If a port-wine stain involves the skin near the eye, glaucoma is a risk and ophthalmic assessment is mandatory.

Treatment of port-wine stains is ideally with the tunable dye (pulsed dye) laser. Facial lesions respond best but lesions can re-darken after some years.

Other conditions in the newborn

Milia

‘Milk spots’ are small follicular epidermal cysts. They are small pinhead white papules commonly found on the face of infants. They resolve spontaneously, unlike in adults.

Mongolian blue spot

This appears in infants as a deep blue-grey bruise-like area, usually over the sacrum or back. It is occasionally mistaken as a sign of child abuse. It is due to deep dermal melanocytes. It is very common in Oriental children, less common in black Africans and rare in Caucasians. It has usually disappeared by the age of 7 years.

image

Urticaria pigmentosa (mastocytosis) and Mongolian blue spots in a baby.

Toxic erythema of the newborn (erythema neonatorum)

Toxic erythema of the newborn is a term used to describe a common transient blotchy maculopapular rash in newborns. The rash is occasionally pustular but the child is not toxic or unwell. It disappears spontaneously within a few days.

Nappy rash (‘diaper dermatitis’)

This is an irritant eczema caused by occlusion of faeces and urine against the skin. It is almost universal in babies. The flexures are usually spared, which is a useful differentiating feature from seborrhoeic and atopic eczema. If satellite lesions are present around the edge it may indicate a superimposed Candida infection. This rash can also occur in the elderly incontinent.

Treatment involves frequent changing of the nappy and regular application of a barrier cream.

Acrodermatitis enteropathica (p. 213)

This is due to a rare inherited deficiency of zinc absorption. It presents 4–6 weeks after weaning or earlier in bottle-fed babies. There is an erythematous, sometimes blistering, rash around the perineum, mouth, hands and feet. It may be associated with photophobia, diarrhoea and alopecia.

Treatment is with lifelong oral zinc, which seems to override the poor absorption. The response is rapid.

Human immunodeficiency virus and the skin

HIV infection (p. 171) commonly causes significant dermatological problems and a rash may even be the presenting feature of underlying HIV infection. These rashes can often be clinically atypical and difficult to diagnose, and skin biopsy and skin culture is sometimes required for diagnosis. Many of the skin problems are resistant to standard treatments, but HAART (p. 171) has decreased the prevalence.

Cutaneous infection and opportunistic infection are increased due to HIV-induced immune deficiency. Molluscum contagiosum is particularly common, especially on the face. Lesions are often multiple and of a ‘giant’ size measuring over 1 cm across. Molluscum is rarely seen in immunocompetent adults but can be the presenting feature of HIV. Other viral infections such as extensive ulcerative herpes or widespread viral warts are seen. Bacterial infections (e.g. staphylococcal boils) and fungal infections (e.g. ringworm and Candida) are also common. Recalcitrant and recurrent oropharyngeal candidiasis is a particular problem.

Opportunistic infections such as cutaneous cytomegalovirus (pustules or necrotic ulcers), sporotrichosis (linear nodules) or Cryptococcus (red papules, psoriasiform or molluscum-like lesions) can pose diagnostic difficulties, stressing the need for skin biopsy and culture.

Inflammatory dermatoses show an increased incidence with HIV infection, probably due to an immune dysfunction or imbalance. Severe, extensive seborrhoeic eczema is very common and is often a presenting sign of HIV. Ichthyosis (dry scaly skin), nodular prurigo, pruritus and psoriasis are all more common in HIV infection and can be very severe. The treatment of these conditions can be difficult in patients who have low CD4 counts (<200/mm3), as oral immunosuppressive therapies (e.g. prednisolone, ciclosporin) are best avoided. Topical therapies and phototherapy seem relatively safe and oral retinoids are a safe option for psoriasis.

‘Autoimmune dermatoses’ such as bullous pemphigoid, thrombocytopenic purpura and vitiligo seem to be increased in incidence. The aetiology is related to polyclonal stimulation of B lymphocytes by HIV with a resulting abnormal antibody production. Erythroderma is sometimes seen in HIV disease where skin biopsy suggests a ‘graft-versus-host disease’ mechanism. This presumably reflects a severe underlying immune dysfunction of T lymphocyte control.

Adverse drug rashes are much commoner in HIV patients. Reactions to co-trimoxazole, dapsone (used in Pneumocystis prophylaxis) and antiretroviral drugs appear particularly common. Drug rashes may be severe (especially with nevirapine and efavirenz), resulting in erythroderma or toxic epidermal necrolysis. Other unusual rashes include a striking nail/mucosal pigmentation from zidovudine, paronychia from indinavir and facial lipodystrophy mostly from protease inhibitors.

Cutaneous tumours. Benign tumours such as extensive persistent viral warts and melanocytic naevi are more common with HIV infection. Pre-malignant conditions such as the intraepithelial dysplasias (cervix CIN, penis PIN, anal AIN) are all much increased possibly due to persistent HPV infection. The risk of malignant transformation in all these three sites is high and should be screened for.

Kaposi’s sarcoma (p. 1226) is much commoner in men who have sex with men with HIV than other groups. Basal and squamous cell carcinomas are also increased in incidence, presumably reflecting a loss of immune surveillance.

Interestingly, HAART has had little impact on reducing rates of anal, penile or cervical cancer and although Kaposi’s sarcoma seemed to almost disappear early on when CD4 counts rose it now has shown a resurgence recently even in those with high CD4 counts and fully suppressed virus.

‘Specific’ HIV dermatoses

‘Itchy folliculitis’ of HIV

Itchy folliculitis (also called papular pruritic eruption) is common in HIV as CD4 counts decline. Its aetiology is unknown. The previously described staphylococcal folliculitis, eosinophilic folliculitis, pityrosporum folliculitis, and demodex mite folliculitis are probably all part of a spectrum and the term ‘itchy folliculitis’ is useful to encompass these. It presents with intensely itchy papules centred on hair follicles and occurring most commonly over the upper trunk and upper arms (Fig. 24.41). The face is more commonly involved in black patients. Individual lesions frequently have the top scratched off, leaving a crateriform appearance. Treatment with oral minocycline, potent topical steroids and emollients help. Phototherapy or oral isotretinoin is useful in resistant cases.

image

Figure 24.41 Itchy folliculitis of HIV infection on upper trunk and proximal limbs.

Oral hairy leucoplakia

This is characterized by white plaques with vertical ridging on the sides of the tongue. Unlike with oral Candida the lesions cannot be peeled off. It was first recognized in HIV disease but can rarely occur in other forms of immunosuppression. It is thought to be due to co-infection with Epstein–Barr virus.

Treatment is with aciclovir, ganciclovir or foscarnet.

Immune reconstitution inflammatory syndrome (IRIS)

Many infections can ‘newly’ present 2–4 months into HAART as CD4 counts are rising: so-called IRIS. Most commonly described are ano-genital HSV, viral warts, tinea folliculitis, molluscum and genital warts. It occurs in up to 25% of patients on HAART. It may simply reflect that the recovering immune system can now react against pathogens that were already present.

FURTHER READING

Rodgers S, Leslie KS. Skin infections in HIV-infected individuals in the era of HAART. Curr Opin Infect Dis 2011; 24:124–129.

Dermatoses of pregnancy

There are a number of minor skin changes during pregnancy. There is an increase in spider naevi, melanocytic naevi, skin tags and chloasma. The abdomen shows midline pigmentation (linea nigra) and striae (stretch marks). There are four less common skin problems associated with pregnancy.

Polymorphic eruption of pregnancy (PEP, also called ‘pruritic urticarial papules and plaques of pregnancy’)

This rash tends to appear in the last trimester of a first pregnancy in 1 in 160 cases. It is of unknown aetiology and recurs only rarely in subsequent pregnancies. It presents with very itchy urticated papules and plaques and occasionally small vesicles. Lesions usually start on the abdomen and striae but may spread to the upper arms and thighs. The umbilicus may be spared. PEP is commoner in twin pregnancies. The rash is not associated with any maternal or fetal risk. PEP has recently been shown to be associated with low maternal serum cortisol levels.

Treatment is with reassurance, bland emollients and mild topical steroids. The rash disappears after childbirth.

Prurigo of pregnancy

Prurigo of pregnancy affects 1 in 300 pregnancies. It usually starts on the abdomen in the 3rd trimester but may persist for some months after delivery. Clustered excoriated papules (prurigo-like lesions) occur on the abdomen and extensor surfaces of the limbs. The cause is unknown but pregnancy-related itch (pruritus gravidarum) may be due to cholestasis (p. 346). Rarely liver biochemical tests are abnormal and urinary HCG levels may be elevated. It can recur in subsequent pregnancies. Some authors believe the condition is associated with an increase in fetal mortality but this remains controversial.

Treatment is with topical steroids and oral antihistamines.

Pruritic folliculitis of pregnancy

This occurs in the 2nd or 3rd trimester of pregnancy and is characterized by an itchy folliculitis which looks similar to steroid-induced ‘acne’. It is not associated with any increased maternal or fetal risk.

Treatment with topical benzoyl peroxide and hydrocortisone cream helps to relieve symptoms.

FURTHER READING

Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395–404.

Pemphigoid gestationis (herpes gestationis)

This is the rarest of the pregnancy-related rashes (1 in 60 000). The immune changes of pregnancy appear to set off bullous pemphigoid. It is characterized by an itchy blistering urticated eruption that starts on the abdomen but may become widespread. Large bullae may be present. Unlike PEP it can occur early, starting in the 2nd or even 1st trimester of pregnancy, and the umbilicus is often involved. It tends to recur in subsequent pregnancies and at an earlier stage. Diagnosis is confirmed by immunofluorescence studies.

A transient bullous eruption occurs in 5% of infants, presumably due to transplacental passage of the offending antibody. There is no increase in fetal mortality but there is an increased incidence of prematurity and low birth weight which is probably due to the autoantibody causing placental insufficiency.

Treatment of mild cases is with potent topical steroids but most cases will require oral corticosteroids. The steroid dose may need to be increased after delivery as there is often a postpartum flare-up of the disease. The rash can be set off again by the oral contraceptive pill and this should be avoided.

Principles of topical therapy

Dermatology is unique in having such direct accessibility to the affected organ. This allows the use of topical treatments which can avoid certain systemic side-effects.

A topical therapy consists of an active ingredient, an appropriate vehicle or base to deliver this, and often a preservative or stabilizer to maintain the product’s shelf-life. A cosmetically acceptable product is necessary and must be accompanied by instructions to the patients about correct usage as without this compliance tends to be poor. Perfumed or scented products should be avoided.

Bases and their uses

image Creams. A cream is a semisolid mixture of oil and water held together by an emulsifying agent. They need to have added preservatives such as parabens. They are ‘lighter’ and rub in more easily than ointments. They have a high cosmetic acceptability and are useful for topical treatments of the face and hands. Aqueous cream is particularly useful as a soap substitute.

image Ointments. These are semisolid and contain no water, being based usually on oils or greases such as polyethylene glycol (water soluble) or paraffin (fatty). They feel greasy or sticky to the touch. They are the best treatment for dry, flaky skin disorders as they are good at hydrating the stratum corneum and they deliver an active ingredient (e.g. a steroid) more effectively.

If patients dislike the greasy nature of ointments, a cream is better than no treatment at all, but creams are less effective and do have to be used more frequently. A compromise may be to use a cream on the face and an ointment elsewhere (Table 24.18).

image Lotions. These are based on a liquid vehicle such as water or alcohol. They are usually volatile and rapid evaporation promotes a cooling effect on the skin. They are useful for weeping skin conditions and are ideal for use on hairy skin (e.g. the scalp). The cooling effect can be a useful antipruritic. Alcohol-based lotions should be avoided on broken skin as they cause stinging.

image Gels. These are semisolid preparations of high molecular weight polymers. They are non-greasy and liquefy on contact with the skin. They are useful for treating hairy skin (e.g. the scalp).

image Pastes. Pastes contain a high percentage (>40%) of powder in an ointment base. They are thick and stiff and difficult to remove from the skin. They are useful when a treatment needs to be applied precisely to a skin lesion without it smearing on to surrounding normal skin. An example would be dithranol in Lassar’s paste (used on plaques of psoriasis) as dithranol will burn the surrounding normal skin.

Safety of topical steroids

Providing that preparations of appropriate strength are used for the body site being treated, these compounds can be used safely on a long-term intermittent basis (p. 1205). If potent steroids are misused, they will cause skin atrophy manifest as striae, wrinkling, fragility and telangiectasia.

Problems with topical therapies

image Systemic absorption may occur but only if very large areas of inflamed skin are treated topically and especially if the treatment is occluded with bandages or polyurethane films. Neonates are particularly susceptible to this owing to the relative increase in body surface area to volume.

image Contact allergy to topical preparations is not uncommon and may be suspected by unusually resistant disease or by apparent worsening of a condition after application of a substance. It is more common with creams as it is often the result of allergy to the preservative or emulsifying agent. Allergy can also be due to the active ingredient itself (e.g. neomycin or hydrocortisone).

image Folliculitis can occur due to blockage of hair follicles. Creams and ointments should be applied to the skin in the same direction as hair growth to try and prevent this blockage. It is a particular problem with the use of ointments in hot weather (especially if under occlusive bandages) and a lighter cream may be more appropriate at this time.

Bibliography

Burns T, Breathnach S, Cox N, et al. Rook’s Textbook of Dermatology, 8th edn, Oxford: Blackwell Scientific, 2010.

Weedon D, ed. Skin Pathology, 3rd edn, Edinburgh: Churchill Livingstone, 2010.

Significant Websites

http://www.bad.org.uk

British Association of Dermatologists

http://guidance.nice.org.uk/

Dermatology treatment guidelines in UK

http://www.thecochranelibrary.com/view/0/index.html

The Cochrane Database provides systematic reviews of treatment

http://www.evidence.nhs.uk/

Clinical guidelines, systematic reviews, evidence-based synopses, image database

http://www.aad.org

American Academy of Dermatology

http://hardinmd.lib.uiowa.edu/dermpictures.html

Dermatology images (atlas)

http://dermnetnz.org/

Dermatology information and images

http://www.eczema.org

National Eczema Society

http://www.psoriasis-association.org.uk

Psoriasis Association

http://www.vitiligosociety.org.uk

Vitiligo Society

http://www.skin-camouflage.net

British Association of Skin Camouflage

http://www.debra.org.uk

Dystrophic Epidermolysis Bullosa Association

http://www.hairlineinternational.co.uk

Hairline International